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Unbiased Next Generation Sequencing Assays 
Illuminate Idiopathic Meningitis and Encephalitis 
 
Brian D. O’Donovan 
 
ABSTRACT 
Encephalitis and associated conditions (meningitis, myelitis, etc.) are a collection 
of diseases characterized by acute or chronic inflammation of the brain and central 
nervous system (CNS). Diagnosing and treating encephalitis can be challenging given 
the litany of potential infectious, ischemic, metabolic, autoimmune, neoplastic, 
paraneoplastic, parameningeal and toxic causes. Diagnostic approaches in infectious 
and autoimmune etiologies – which account for an overwhelming majority of cases – 
are generally candidate-based panels of nucleic acid (PCR), serological, or cell-based 
assays with limited throughput and often suffer from low sensitivity and specificity. 
Frequently, patients receive no definite diagnosis, are treated empirically at great cost to 
the individual and greater health system, or receive treatments contraindicated to their 
specific condition. Novel, unbiased, and high-throughput diagnostic methods are 
needed to address these challenges. 
Here I present my efforts to develop rapid, cost effective, unbiased, and high-
throughput methods leveraging next generation sequencing (NGS) technologies to 
illuminate the underlying causes of infectious and autoimmune-mediated CNS 
	 viii	
inflammation. I demonstrate the design and implementation of a phage display and 
immunoprecipitation (PhIP-Seq) assay to map the antigenic determinants of 
autoantigens in two paraneoplastic neurological disorders, the anti-Hu and anti-Yo 
syndromes. The assay, leveraging a rationally designed library of phage clones 
expressing >700,000 peptides encompassing the entire human proteome, also serves 
as a discovery platform to identify novel disease-associated antigens and antibody 
binding signatures that may eventually serve as valuable diagnostic and prognostic 
biomarkers in cancer detection and immune repertoire profiling. 
To address challenges in identifying infectious etiologies, I present my efforts in 
applying metagenomic and metatranscriptomic NGS (mNGS) to patient cerebrospinal 
fluid (CSF) samples. The low nucleic acid content of CSF and the sterile, privileged 
nature of the CNS present unique opportunities and challenges for metagenomic 
assays. The complex, noisy, and polymicrobial datasets generated by mNGS require 
careful analysis to determine which, if any, of the identified microbes represent a true 
pathogen versus environmental contamination. Failure to make this distinction can 
result in spurious disease associations with organisms later determined to be laboratory 
contaminants. I demonstrate the necessity and efficacy of a straightforward statistical 
framework coupled with careful study design for identifying microbial pathogens in a 
series of challenging cases of subacute or chronic infectious meningitis, as well as for 
analyzing publicly-available data from recent mNGS diagnostic and brain microbiota 
studies.    
 
 
	 ix	
Contents 
Chapter 1 Background and Introduction ...................................................................... 1	
1.1	 Encephalitis and Meningitis – Prevalence and Diagnostic Challenges .............. 1	
1.2	 Clinical Potential of Next Generation Sequencing (NGS) Technologies ............ 2	
1.3	 Summary of Work and Findings ......................................................................... 3	
1.3.1	 Autoimmune Encephalitis and PhIP-Seq .................................................... 3	
1.3.2	 Infectious Encephalitis and Metagenomics ................................................. 4	
1.3.3	 DASH .......................................................................................................... 5	
Chapter 2 Exploration of Anti-Yo and Anti-Hu paraneoplastic neurological 
disorders by PhIP-Seq reveals a highly restricted pattern of antibody epitopes .... 6	
2.1	 ABSTRACT ........................................................................................................ 6	
2.2	 INTRODUCTION ................................................................................................ 7	
2.2.1	 Paraneoplastic Neurological Disorders ....................................................... 7	
2.2.2	 Anti-Yo PND ................................................................................................ 8	
2.2.3	 Anti-Hu PND ............................................................................................... 9	
2.2.4	 PhIP-Seq .................................................................................................... 9	
2.3	 RESULTS ......................................................................................................... 11	
2.3.1	 Design, Production, and Characterization of PhIP-Seq Library ................ 11	
2.3.2	 Fidelity of Library....................................................................................... 12	
2.3.3	 Development of Statistical Approach to Analyze Peptide Enrichment ...... 13	
2.3.4	 Phage Library Performance Validation:  Commercial Antibodies ............. 15	
2.3.5	 PND Cohort Results.................................................................................. 16	
2.3.6	 Identification of CDR2/CDR2L antigens in anti-Yo samples ..................... 17	
	 x	
2.3.7	 Identification of nELAVL antigens in anti-Hu samples .............................. 18	
2.3.8	 Consensus motif contains subsequences with predicted and 
experimentally demonstrated T-Cell Antigenicity .................................................... 21	
PhIP-Seq Identifies Additional Known and Potentially Novel Autoantigens ............ 23	
2.3.9	 Comparison to Healthy Sera Samples Identifies Potential Disease-
Associated Binding Signatures ............................................................................... 23	
2.3.10	 Zic and Sox Family Enrichment ................................................................ 24	
2.3.11	 Novel PND/Cancer Associated Signatures in Anti-Yo Patients ................ 24	
2.4	 DISCUSSION ................................................................................................... 25	
2.5	 MATERIALS AND METHODS ......................................................................... 30	
2.5.1	 Computational Design of Library .............................................................. 30	
2.5.2	 Cloning into T7 Select vector .................................................................... 31	
2.5.3	 Cloning and Packaging ............................................................................. 32	
2.5.4	 In vivo amplification .................................................................................. 33	
2.5.5	 Concentrating and Storing Phage Library ................................................. 33	
2.5.6	 Immunoprecipitation ................................................................................. 33	
2.5.7	 NGS Library Prep...................................................................................... 34	
2.5.8	 Bioinformatic Analysis ............................................................................... 36	
2.5.9	 Design of Hu Motif Mutational Scanning Library ....................................... 37	
2.5.10	 ELAVL4 amplicon sequencing from bulk thymus and human TECs ........ 38	
2.5.11	 Motif Discovery ......................................................................................... 40	
2.5.12	 Clinical PND Antibody Confirmation ......................................................... 41	
2.6	 FIGURES ......................................................................................................... 42	
	 xi	
2.7	 TABLES ........................................................................................................... 53	
Chapter 3 Metagenomic next-generation sequencing for chronic meningitis: a 
case series .................................................................................................................... 55	
3.1	 ABSTRACT ...................................................................................................... 55	
3.2	 INTRODUCTION .............................................................................................. 56	
3.3	 RESULTS ......................................................................................................... 57	
3.3.1	 Case Descriptions ..................................................................................... 57	
3.3.2	 Background Signature of Reagent and Environmental Contaminants ..... 64	
3.4	 DISCUSSION AND CONCLUSIONS ............................................................... 65	
3.5	 MATERIALS and METHODS ........................................................................... 68	
3.5.1	 mNGS Protocol ......................................................................................... 68	
3.5.2	 Bioinformatics and Statistical Analysis ..................................................... 69	
3.6	 FIGURES ......................................................................................................... 71	
3.7	 TABLES ........................................................................................................... 77	
Chapter 4 Depletion of Abundant Sequences by Hybridization (DASH): using Cas9 
to remove unwanted high-abundance species in sequencing libraries and 
molecular counting applications ................................................................................ 78	
4.1	 ABSTRACT ...................................................................................................... 78	
4.2	 INTRODUCTION .............................................................................................. 79	
4.3	 RESULTS ......................................................................................................... 82	
4.3.1	 Reduction of unwanted abundant sequences in HeLa samples ............... 83	
4.3.2	 Enrichment of non-targeted sequences in HeLa samples ........................ 84	
4.3.3	 Reduction of unwanted abundant sequences in CSF samples ................ 85	
	 xii	
4.3.4	 Reduction of wild-type background for detection of the KRAS G12D 
(c.35G>A) mutation in human cancer samples ....................................................... 86	
4.4	 DISCUSSION ................................................................................................... 88	
4.4.1	 Input requirements .................................................................................... 90	
4.4.2	 Performance ............................................................................................. 90	
4.4.3	 Programmability ........................................................................................ 92	
4.4.4	 Cost ........................................................................................................... 92	
4.5	 CONCLUSIONS ............................................................................................... 94	
4.6	 MATERIALS AND METHODS ......................................................................... 95	
4.6.1	 Generation of cDNA from HeLa cell line and clinical samples .................. 95	
4.6.2	 In vitro preparation of the CRISPR/Cas9 complex ................................... 95	
4.6.3	 CRISPR/Cas9 treatment ........................................................................... 97	
4.6.4	 High-throughput sequencing and analysis of sequencing data ................ 98	
4.6.5	 ddPCR of KRAS mutant DNA ................................................................... 99	
4.6.6	 Ethics ...................................................................................................... 101	
4.6.7	 Availability of data and materials ............................................................ 101	
4.7	 FIGURES ....................................................................................................... 102	
4.8	 TABLES ......................................................................................................... 109	
REFERENCES ............................................................................................................. 110	
 
 
 
 
 
 
 
	 xiii	
List of Figures 
 
Figure 2.1 - Design and Characterization of Library.	...........................................................	42	
Figure 2.2 - Validation of library by commercial antibody IP's.	...........................................	43	
Figure 2.3 - Anti-Yo representative results.	...........................................................................	44	
Figure 2.4 - Anti-Yo epitope mapping.	....................................................................................	46	
Figure 2.5 - Anti-Hu epitope mapping.	...................................................................................	48	
Figure 2.6 - Patient 01 samples dominated by ELAV motif.	................................................	49	
Figure 2.7 - Anti-CRMP5 epitope mapping.	...........................................................................	50	
Figure 2.8 - Scaling and normalizing peptide fold-change values.	.....................................	51	
Figure 2.9 - PhIP-Seq Identifies short exon in ELAVL4 excluded in thymus.	...................	52	
Figure 3.1 - Diagram of a rapid computational pipeline.	......................................................	71	
Figure 3.2 - Ranked Results of Statistical Scoring.	..............................................................	72	
Figure 3.3 - Selected Neuroimaging.	......................................................................................	73	
Figure 3.4 - Background signature of reagent and environmental contaminants.	...........	74	
Figure 3.5 - RNA doping experiment.	.....................................................................................	76	
Figure 4.1 - DASH conceptual figure	....................................................................................	102	
Figure 4.2 - DASH targeting abundant mitochondrial rRNA in Hela extrations	..............	103	
Figure 4.3 - DASH'ed clinical samples.	................................................................................	104	
Figure 4.4 - DASH in cancer.	.................................................................................................	105	
Figure 4.5 - Concentration-dependent depletion.	...............................................................	106	
Figure 4.6 - Mitochondrial rRNA target sites in mtRNR2L12	............................................	107	
Figure 4.7 - Patient-specific scatterplots.	.............................................................................	108	
	 xiv	
List of Tables	
	
Table 2.1 - Significant antigen-disease associations. .................................................... 53 
Table 2.2 - Preferred E. coli codons used in library design. ........................................... 54 
Table 3.1 - Clinical characteristics of study participants ................................................. 77 
Table 3.2 - Metagenomic sequencing summary ............................................................ 77 
Table 4.1 - Summary of depletetion/enrichment results in DASH-treated CSF ........... 109 
Table 4.2 - sgRNA targeted sequences ....................................................................... 109 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
1	
	
	
	
	
	
	
	
Chapter 1  
 
 
Background and Introduction 
	
	
	
1.1 Encephalitis and Meningitis – Prevalence and Diagnostic Challenges  
  
Encephalitis, meningitis, and many closely associated conditions (myelitis, CNS 
vasculitis, etc.) are a set of diseases characterized by acute or chronic inflammation of 
the brain and central nervous system (CNS). In the US, encephalitis accounts for over 
20,000 hospitalizations annually with a mortality rate of 6% and estimated in-patient 
cost of $2 billion.1,2 A major contributor to this disease burden is the fact that CNS 
inflammation presents a unique diagnostic challenge given the litany of potential 
infectious, ischemic, metabolic, autoimmune, neoplastic, paraneoplastic, parameningeal 
and toxic causes. Diagnostic approaches in infectious and autoimmune etiologies – 
which account for an overwhelming majority of cases – are generally low-throughput, 
candidate-based panels of nucleic acid (PCR), serological, or cell-based assays (CBAs) 
and often suffer from low sensitivity and specificity. As many as 40-70% of patients 
receive no definite diagnosis,2 are treated empirically at great cost to the individual and 
greater health system, and can receive treatments contraindicated to their specific 
condition (immune suppression during viral infections, for example) as physicians act in 
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good faith but with limited information. Novel, unbiased, and high-throughput diagnostic 
methods are needed to address these challenges and better understand the underlying 
mechanisms that lead to CNS inflammation.  
 
1.2 Clinical Potential of Next Generation Sequencing (NGS) Technologies 
	
Next Generation Sequencing (NGS) describes a suite of platforms and 
technologies defined by the ability to sequence millions of small DNA fragments in 
parallel.3 The impact of NGS on molecular biology research and our understanding of 
the natural world cannot be understated. NGS has ushered in a revolution in biomedical 
research and genomic data is estimated to become the largest source of digital 
information in world by 2025.4 Despite its relatively ubiquitous station in the basic 
research laboratory, adoption and implementation of NGS technologies in the clinical 
context has been slower. This has been in part due to the cost and availability of 
sequencing, accompany data storage and compute requirements, and the appropriate 
regulatory due diligence necessary in adopting new methodologies in the higher-stakes 
medical field.  
Major declines in sequencing costs, distributed (“cloud-based”) compute and 
data storage solutions, and increased availability and familiarity with the technology in 
medical community has enabled NGS to make substantial inroads in recent years. The 
growing consensus is that NGS is poised to precipitate a similar revolution in medicine, 
having already made significant contributions in prenatal testing,5 cancer screening and 
genotyping,6 and infectious disease diagnosis and monitoring.7 Integration of whole 
exome or single nucleotide polymorphism (SNP) panel data with electronic medical 
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records (EMRs) will enable novel disease-genotype associations, drug response 
prediction and stratification, and reveal novel, polygenic disease phenotypes that have 
thus far eluded clinical understanding. Further, NGS will continue to precipitate 
discoveries in basic research that will expand our understanding of the molecular basis 
for disease and undoubtedly have translational implications.   
In this dissertation, I present my work and efforts in applying NGS technologies 
to developing rapid, cost-effective, high-throughput assays for the diagnosis and 
understanding of autoimmune and infectious causes of encephalitis. While each chapter 
is meant to be self-contained or is based on previously published material, a brief 
summary of the history, motivation and context of each chapter/project is in order.   
 
1.3   Summary of Work and Findings 
 
1.3.1 Autoimmune Encephalitis and PhIP-Seq 
	
Autoimmune encephalitis describes a disease process wherein the patient’s own 
immune system fails to maintain the ability to distinguish “self” from “non-self” and the 
arsenal of cellular and molecular sentinels that normally protect the body from infection 
or malignant neoplasm are brought to bear against the patient’s CNS cells and tissues. 
The mechanisms leading to autoimmunity vary are not fully understood, and the array of 
potential endogenous target proteins, known as autoantigens, is as heterogeneous as 
the human proteome. In chapter 2 of this work, I describe the design and 
implementation of a programmable phage display library and automated, robotics-based 
immunoprecipitation and sequencing protocol (PhIP-Seq) that allows the simultaneous 
screening of dozens of patient samples for antibodies that bind to all possible 
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endogenous peptide antigens. The data provides a high-resolution snapshot of antibody 
binding signatures and can map antigenic determinants with single amino acid 
resolution. I apply PhIP-Seq to two common paraneoplastic conditions, the anti-Hu and 
anti-Yo syndromes, though the technique is applicable to any autoimmune disorder. I 
characterize the binding signatures to the canonical Yo and Hu antigens while 
identifying several known and novel disease-associated autoantigens. The data 
provides insight into the oncoimmune processes underpinning the rise of autoimmunity 
and identifies several potentially novel diagnostic and prognostic biomarkers in 
paraneoplastic encephalitis and cancer.    
 
1.3.2 Infectious Encephalitis and Metagenomics 
	
 The CNS has unique anatomic and immunologic characteristics that make it 
particularly vulnerable to infection from foreign microbes.8 Despite ostensible protection 
from the “blood-brain barrier,” hundreds of environmental and commensal bacteria, 
viruses, fungi, protozoa, helminths and eukaryotic parasites are known to infect all 
levels and anatomic structures of the CNS - proliferating with impunity in the 
immunologically “privileged” environment.9 Roughly half of all hospitalizations related to 
CNS inflammation are considered to be infectious, though limitations of existing 
diagnostic assays mean that often no etiologic pathogen is ever identified.2  
Metagenomics is the study of all genetic material and associated taxa in a 
biological sample. Using metagenomic NGS (mNGS) to identify pathogens in infectious 
disease is perhaps the most salient clinical application of NGS technology. In chapter 3 
of this dissertation, I outline my efforts to apply mNGS to cerebrospinal fluid samples 
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(CSF) and develop statistical approaches and study design standards to identify the 
causative pathogen in a series of acute and chronic cases of infectious meningitis. I 
demonstrate and emphasize the need for robust statistical and methodological 
approaches in analyzing the inherently complex and polymicrobial datasets generated 
by mNGS to avoid false positives and potential misdiagnosis. I apply my approach to 
publicly available data from recent publications implicating common laboratory reagent 
contaminants in CNS infection or purporting the existence of a brain or CNS 
microbiome.10 
 
1.3.3 DASH 
	
 In analyzing hundreds of clinical mNGS datasets in the DeRisi lab, it became 
apparent that only a minute fraction (often <0.1%) of the sequencing data “reads” were 
derived from causative pathogen. A huge majority of reads were attributed to a small 
number of ubiquitously expressed human mitochondrial genes that were filtered out and 
otherwise ignored in our computational pipeline. These reads consume valuable storage 
and compute space and increase the requisite depth of sequencing required to detect 
the low abundant species in a sample. In chapter 4, I describe a simple and 
programmable biochemical method devised to remove unwanted sequences in 
oligonucleotide libraries just prior to loading on the sequencing platform. The method, 
dubbed Depletion of Abundant Sequences by Hybridization (DASH), leverages the 
programmable and specific exonuclease activity of the Cas9 protein and proved to be 
an easy, cost efficient, and highly effective solution to a problem that plagues many 
NGS applications.  
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Chapter 2  
 
Exploration of Anti-Yo and Anti-Hu paraneoplastic 
neurological disorders by PhIP-Seq reveals a highly 
restricted pattern of antibody epitopes 
	
 
2.1 ABSTRACT 
	
Paraneoplastic neurological disorders (PNDs) are immune-mediated diseases of 
the nervous system understood to manifest as part of a misdirected anti-tumor immune 
response. Identifying PND-associated autoantibodies and their cognate antigens can 
assist with proper diagnosis and treatment while also enhancing our understanding of 
tumor-associated immune processes, triggers for autoimmune disease, and the 
functional significance of onconeuronal proteins. Here, we employed an enhanced 
version of phage display immunoprecipitation and sequencing (PhIP-Seq) leveraging a 
library of over 731,000 unique phage clones tiling across the entire human proteome to 
detect autoantibodies and create high-resolution epitope profiles in serum and CSF 
samples from patients suffering from two common PNDs, the anti-Yo (n = 36 patients) 
and anti-Hu syndromes (n = 44 patients). All patient samples positive for anti-Yo 
antibody by a validated clinical assay yielded polyspecific enrichment of phage 
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presenting peptides from the canonical anti-Yo (CDR2 and CDR2L) antigens, while 38% 
of anti-Hu patients (17/44) had a serum and/or CSF sample that significantly enriched 
peptides deriving from the ELAVL family of proteins, the anti-Hu autoantigenic target. 
The anti-Hu antibodies showed a remarkably convergent antigenic signature across 
15/17 patients corresponding to residues surrounding and including the degenerate 
motif, RLDxLL, shared by ELAVL2, 3 and 4. Lastly, PhIP-Seq identified several known 
and novel autoantigens in these same patient samples, representing potential 
biomarkers that could aid in the diagnosis and prognosis of PND and cancer. 
 
2.2 INTRODUCTION 
	
2.2.1 Paraneoplastic Neurological Disorders 
	
Paraneoplastic neurological disorders (PNDs) affecting the central nervous 
system (CNS) are a collection of diseases characterized by an autoimmune response to 
proteins nominally restricted to the CNS and triggered by ectopic expression of the 
antigen by a systemic neoplasm.11 Neurologic symptoms of PNDs vary and can reflect 
damage to essentially any level of the neuroaxis. This symptom variability is, in part, 
determined by the neuroanatomic and/or cell type specificity of each PND. Existing PND 
pathogenesis models posit that an otherwise effective anti-tumor immune response to 
tumor antigens precipitates a breakdown of immune tolerance and subsequent 
infiltration of autoreactive lymphocytes and/or pathogenic autoantibodies into the CNS.12 
The roles and culpability of cell-mediated and humoral immune responses in disease 
progression are disputed, as onconeuronal antibodies are often specific for intracellular 
proteins and are frequently detected in the sera of cancer patients in the absence of 
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PND symptoms.13 In a typical clinical presentation, the neurological deficits and 
symptoms manifest before any underlying cancer is detected. As such, patients 
presenting with PND symptoms and tumor-associated antibodies are presumed to have 
cancer until otherwise ruled out and long-term tumor monitoring is recommended. 
Patients developing PND symptoms have lower rates of metastasis and higher rates of 
cancer survival, likely a consequence of the otherwise appropriate oncoimmune 
response. Additionally, a majority of PND patients test positive for multiple tumor/PND 
related autoantigens.14 Antibody specificities are thought to be reflective of a tumor’s 
onconeural antigen expression, and clusters of neural autoantibodies in a patient’s 
serum or CSF can aid in specific cancer diagnosis.15 
 
2.2.2 Anti-Yo PND 
	
Anti-Yo paraneoplastic cerebellar degeneration (PCD) accounts for roughly 50% 
of subacute PCD presenting in middle age.16 The disease is marked by severe 
cerebellar ataxia, dysarthria, and Purkinje cell death and almost exclusively affects 
women, as it is primarily associated with gynecological and breast malignancies.17 Anti-
Yo antibodies, also known as anti-Purkinje cell cytoplasmic antibody 1 (PCA-1), target 
the two intracellular proteins CDR2 (cerebellar degeneration related protein 2) and/or 
CDR2L (CDR2-like). Little is known about the function of these proteins other than that 
they have a role in transcription and that their expression is primarily limited to Purkinje 
neurons in the cerebellum, the brainstem, and spermatagonia.18  Whether the 
antibodies alone have pathogenic potential remains controversial; however, it is 
generally accepted that specific CD8+ T cells lead to Purkinje cell death.19 Although 
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disease prognosis is poor, early detection,  immunosuppression, and successful cancer 
treatment can limit Purkinje neuron loss and improve patient outcomes.20 To date, the 
specific antigenic determinants on the CDR2 and CDR2L proteins have not been 
mapped. 
 
2.2.3 Anti-Hu PND 
	
Anti-Hu-related PND is most commonly associated with small cell lung cancer 
(SCLC) and can present with differing neurologic syndromes ranging from 
dysautonomia, encephalopathy (limbic, brainstem, multifocal), epilepsy, cerebellar 
degeneration, myelopathy, and polyneuropathy.21 Anti-Hu antibodies target members of 
the ELAVL (embryonic lethal abnormal vision like) family of intracellular RNA-binding 
proteins. There are 4 members of this family, ELAVL1, ELAVL2, ELAVL3, and ELAVL4 
(also known as HuA/R, HuB, HuC, and HuD, respectively). ELAVL1 is the most 
divergent homolog and is ubiquitously expressed in all tissues, while ELAVL2, 3, and 4 
have restricted expression to the nervous system and are often referred to as nELAVL 
proteins (neuronal ELAVL).22  
 
2.2.4 PhIP-Seq 
	
The majority of currently available clinical autoimmune panels include antigen-
specific ELISA-based methods, cell-based assays (CBAs), co-localization 
immunohistochemistry (IHC), and traditional western blots.23 These candidate-based or 
single antigen tests may not capture the true complexity of the presumably more 
heterogeneous oncoantigenic repertoire. Unbiased and higher throughput methods exist 
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in the research context and include immunoprecipitation-mass spectrometry (IP-MS), 
expression library screening, biochemical purification, peptide arrays, protein arrays, 
and phage display, each with its own advantages and limitations. Among these, 
variations on bacteriophage display technologies have been successfully utilized for 
decades in antigen discovery,24 epitope mapping,25 and antibody engineering.26 
Traditionally, tissue-specific cDNA libraries or degenerate or random synthetic 
oligonucleotides are cloned and expressed on the surface of phage capsids which are 
panned against immobilized antibody or other targets of interest. More recently, 
rationally designed libraries encompassing the entire human proteome have been 
implemented.27 With next generation sequencing (NGS) as a readout, researchers can 
quantify the enrichment of millions of individual phage clones simultaneously and 
identify sequences that bind to the target or antibody of interest. This technology, known 
as Phage Immunoprecipitation and Sequencing (PhIP-Seq), enables high-throughput 
screening of patient samples and has successfully identified autoantigens and mapped 
epitopes in inclusion body myositis, rheumatoid arthritis, as well as two other common 
PNDs, the anti-Ma and anti-Ri syndromes.28  While broad spectrum autoantibody 
screening has previously been considered to be cost prohibitive,29 the continuing 
decline of large scale olignonucleotide synthesis and NGS costs may make whole 
proteome screening in by PhIP-Seq increasingly accessible in both research and clinical 
contexts.  
Inspired by the potential of this technology to build upon our existing studies into 
the underlying causes of meningitis and encephalitis, we expanded on the published 
PhIP-Seq technique by designing a larger, more comprehensive library of endogenous 
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human peptides. Our human “peptidome” consists of 731,724 unique phage clones and 
includes all known and predicted human protein splice variants. Using this expanded 
library, we conducted nearly 800 immunoprecipitations over 130 serum and CSF 
samples from patients suffering from anti-Hu and anti-Yo PNDs, revealing the most 
comprehensive and highest resolution epitope mapping of the autoantigens targeted in 
these PNDs to date. For the unusually convergent Anti-Hu epitope, additional deep-
mutational scanning phage libraries where employed to map binding determinants at 
the single amino acid level. The results presented here further demonstrate the utility 
and high-resolution capability of programmable phage display for both basic science 
and clinical applications.   
 
2.3 RESULTS 
	
2.3.1 Design, Production, and Characterization of PhIP-Seq Library 
 
The Human PhIP-Seq Library v2 contains all annotated human protein 
sequences from the NCBI protein database as of November 2015, including all 
published and computationally predicted splice variants and coding regions (Figure 1). 
Full-length sequences were clustered on 99% sequence identity (CD-HIT v4.6)30 to 
remove duplicate and partial entries, resulting in a set of 50,276 proteins. Each protein 
was computationally divided into 49 AA peptides using a 24 AA sliding window 
approach such that sequential peptides overlapped by 25-residues (see Methods). This 
resulted in a set of 1,256,684 peptide sequences encompassing the entire human 
proteome. To remove redundant sequences derived from identical regions of the 
various isoforms and homologs, we further clustered and collapsed the 49 AA peptides 
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on 95% identity such that peptides with 2 or fewer AA differences were combined by 
choosing one representative sequence. 
Amino acid sequences were converted to nucleotides using preferred E. coli 
codons (see Methods).31 Restriction sites (EcoRI, HindIII, BamHI, XhoI) were removed 
with synonymous nucleotide changes to facilitate cloning. To enable amplification from 
synthesized oligo pools, 21 nucleotide (nt) universal priming sites were added to the 5’ 
and 3’ ends of each sequence. These priming sites also encoded STREP and FLAG tag 
sequences (after addition of a terminal codon by PCR). Thus, the final library consisted 
of 731,724 unique 189mer oligonucleotide sequences encoding 49 AA human peptides 
flanked by 5’-STREP and 3’-FLAG sequences. The library was synthesized by Agilent 
Technologies (Santa Clara, CA) in three separate pools.  The complete sequence of 
each oligo is available at https://github.com/derisilab-ucsf/PhIP-PND-2018. 
 
2.3.2 Fidelity of Library 
	
  After PCR amplification and size selection (Blue Pippin 3% Agarose cassette, 
Sage Science, Beverly, MA) but prior to cloning and packaging into phage, the 
synthesized oligos were evaluated by NGS with 70 million paired-end 125 nt reads 
(Figure 1B). 98.5% of all the synthesized sequences were full length, and 84% were 
error free. For those with errors, a majority (10% of all sequences) were deletions of 3 
or fewer bases, while single base substitutions accounted for 4%, and the remaining 2% 
of oligos contained larger deletions (> 4 bases) or truncated/chimeric sequences. The 
commercially synthesized library yielded 722,436 unique peptide sequences with an 
estimated Chao1 diversity of 723,421, indicating that 99% of the library was present. 
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The distribution and coverage of the library was uniform, with 99.9% of the sequences 
within ten-fold of the expected fraction (Figure 1C). 
Size-selected and restriction-digested oligos were cloned and packaged in 25 
separate 10 μl reactions according to the manufacturer’s specifications (EMD, 
Burlington, MA). The efficiency of in vitro packaging was quantified by plaque assay. 
The diluted and quenched packaging reaction (3 ml total) contained 109 plaque forming 
units (pfu)/ml, roughly 1000x coverage of the entire library. The library of phage clones 
was sequenced (70 million paired-end 125 nt reads) to determine the fidelity of the 
packaged library. 77% of phage sequenced yielded error-free, full-sized inserts (Figure 
1). The majority of errors (21% of all sequences) were deletions or stop codons 
resulting in shorter expressed peptides. Within the 77% of correct sequences, there 
were 657,948 unique clones with an estimated Chao1 diversity of 658,476 – indicating 
that 89% of this library was packaged and cloned without any errors. Allowing for 
synonymous mutations and single amino acid substitutions, 92% of the library was 
packaged successfully into phage. 
 
2.3.3 Development of Statistical Approach to Analyze Peptide Enrichment 
	
Several statistical approaches for analyzing PhIP-Seq data have been published, 
primarily based on Generalized Poisson (GP) or Negative Binomial (NB) count models 
fit to the distribution of unselected or input library phage populations.32,33  More recently, 
an algorithm leveraging z-scores of phage counts relative to AG bead only “mock” IPs 
was developed to account for non-specific phage binding to IP reagents and 
substrates.34  These approaches were developed to analyze datasets generated from 
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single rounds of immunoprecipitation and were optimized for sensitivity to low 
abundance phage.  
In order to identify phage significantly enriched after multiple consecutive rounds 
of selection with patient antibodies, a statistical framework was developed (see 
Methods) based on phage fold-change statistics relative to a collection of 40 
independent mock IPs using protein-AG beads alone. Briefly, peptide counts from each 
control and sample IP were normalized to reads per 100,000 (rpK). Normalized peptide 
counts from each experimental IP were multiplied by a sample-specific scaling factor 
derived from the median rpK of the 100 most highly and consistently enriched AG-bead 
binding peptides (Figure 2.8, sequences available at: https://github.com/derisilab-
ucsf/PhIP-PND-2018). Each peptide’s fold-change enrichment was then calculated by 
dividing its scaled rpK value by its mean representation in the AG controls. Given the 
nature of the fold-change calculation, small fluctuations in low abundance phage in 
control IPs can lead to inflated fold-change values and false positives. To address this, 
fold-change values were further transformed using a method inspired by smoothed 
quantile normalization approaches in microarray data (see Methods).35 P-values were 
assigned to the fold-changes by evaluating the survival function of a normal distribution 
fit to the log10(fold-change) values in each experimental batch. Peptides reported as 
significant were those having an adjusted p-value (padj) =< 0.05 in at least two replicates 
after multiple test correction (Benjamini-Hochberg).36 
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2.3.4 Phage Library Performance Validation:  Commercial Antibodies 
	
Validation of the PhIP-Seq protocol was performed using two commercial 
antibodies with known specificities: anti-glial fibrillary acid protein (GFAP) 
(Agilent/DAKO, Carpinteria, CA) and anti-gephyrin (GPHN) (Abcam, Burlingame, CA) 
polyclonal antibodies. Three rounds of enrichment were used to further select for the 
particular epitope and reduce the proportion of non-specific binders. After each round of 
enrichment, phage populations were assessed by sequencing to an average depth of 2 
million paired-end 125 nt reads. After 3 rounds of enrichment, a majority (50-70%) of the 
phage in the final population encoded peptides derived from the commercial antibody 
target (Figure 2.2A). Replicate IPs were conducted on separate days and exhibited high 
reproducibility (r > 0.8) in phage counts between experiments.  
When applied to these data, our statistical model correctly identified peptides 
from the target gene of interest as the most significantly enriched with minimal off-target 
or unrelated peptides/genes (Figure 2.2B).  The anti-GFAP IPs enriched 18 unique 
peptides representing > 60% of all phage in the final library (in both replicates) and 
scaled fold-changes greater than 300,000x (padj < 10-20) over the mock IPs. Similarly, 
the anti-GPHN commercial antibody enriched 4 unique C-terminal gephyrin peptides 
with 10,000-fold enrichment (padj < 10-25) over control IPs.  
Alignment of the significantly enriched peptides from the anti-GFAP IP to the full-
length protein revealed a distinct antigenic profile (Figure 2.2C), suggesting the 
commercial antibodies had highest affinity for a ~27 AA region surrounding the exon 5-6 
junction. Notably, this region was identified by the immune Epitope Database (IEDB) 
tools Emini Surface Exposure calculation as having the highest B cell antigenicity 
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potential.37 The three significantly enriched GPHN peptides were all overlapping 
sequences with consensus at the final 32 residues of the surface exposed C-terminus 
(Figure 2.2D). The anti-GPHN IPs also consistently enriched a single peptide from 
chromogranin A (CHGA) at levels greater than or commensurate with that of the GPHN 
peptides (padj < 10-30). Motif analysis (GLAM2)38 and alignment of the CHGA and GPHN 
phage-peptides, revealed a discontinuous 6-residue sequence (YxExxK) shared 
between CHGA and GPHN. Of the 256 peptides reported as significant in both 
replicates, 144 peptides (56%), contained the motif (Figure 2.2D). The probability of 
recovering these motif-containing peptides by chance given their representation in the 
original library is infinitesimal (< 10-300, Fischer’s exact test), indicating that a majority of 
the peptides in the final phage population were, in fact, true binders to the commercial 
antibody. These data also demonstrated that single AA resolution binding motifs could 
be recovered given sufficient representation in the original library. 
 
2.3.5 PND Cohort Results  
	
In total, 798 individual IPs (including all three rounds of enrichment) were 
performed on 130 CSF and serum samples from patients with anti-Yo or anti-Hu 
antibodies identified by the Mayo Clinic Neuroimmunology Laboratory with CLIA and 
New York State approved methodology, as previously described (see Methods).39 The 
PhIP-Seq protocol was performed on a Biomek FX (Beckman Coulter, Brea, CA) 
automated liquid handler across three experimental batches (see Methods). All samples 
were run blinded and in duplicate. A sample was reported as positive if peptides derived 
from the respective Yo (CDR2/CDR2L) or Hu (ELAVL2,3,4) antigens showed significant 
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fold-changes (padj  <= 0.05) in both replicates. Files containing the peptide counts for 
each IP are available at https://github.com/derisilab-ucsf/PhIP-PND-2018, and raw data 
are available under NCBI BioProject Accession PRJNA506115. 
 
2.3.6 Identification of CDR2/CDR2L antigens in anti-Yo samples 
	
From 36 confirmed anti-Yo patients, a total of 53 samples were interrogated by 
PhIP-Seq, of which 51 (96%) were positive for anti-Yo peptides. When sample identities 
were unblinded, it was revealed that all 36 patients were represented by these positive 
samples. No significant differences were observed in sensitivity or binding profiles 
between CSF and serum, with 34/36 sera and 17/20 CSF testing positive (pchi-square = 
0.23). From 50 de-identified healthy donor sera, only a single CDR2L peptide from a 
single donor was significantly enriched (37 rpK, padj = 0.0494). 
As shown in Figure 2.3A for three representative patients, phage specific for 
CDR2/CDR2L dominated the population by the final round of selection in a majority of 
samples. All patients showed enrichment for CDR2L while 30/36 (83%) were positive for 
both CDR2L and CDR2 peptides. No patients showed reactivity to CDR2 peptides 
alone. Across all patients, 29 unique CDR2L peptides were identified and accounted for 
21% of all phage sequenced. Conversely, 6 unique peptides from CDR2 were identified 
across all patient samples and accounted for 0.25% of all phage sequenced (Figure 
2.3B), suggesting that the overall magnitude and complexity of peptide enrichment for 
CDR2L was greater than for CDR2 peptides. 
The antigenic profile across the full length CDR2L protein, for all 36 patients, is 
shown in Figure 2.4A. Convergent epitopes were shared by subgroups of patients, 
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particularly at residues 322-346, the most highly enriched epitope across all patients. In 
contrast to CDR2L, the antigenic profile of patient antibodies to CDR2 (Figure 2.4C) 
was primarily limited to 3 peptides spanning the 100 AA at the N-terminus. We further-
examined the relationship between homology and enrichment (Figure 2.4B). 
Interestingly, the most highly enriched regions of CDR2L represented the most 
divergent regions between the two proteins, suggesting that the antibody responses to 
CDR2L and CDR2 are independent and patient antibodies are, in fact, preferentially 
enriching for CDR2L over CDR2. 
 
2.3.7 Identification of nELAVL antigens in anti-Hu samples 
	
From 44 patients with laboratory confirmed anti-Hu PND, a total of 76 samples 
(32 paired serum/CSF, two CSF, and 10 serum) were subjected to PhIP-seq. A total of 
19 samples from 13 patients resulted in significantly enriched peptides (in both 
replicates) derived from the nELAVL genes (ELAVL2, ELAVL3, and ELAVL4), the 
known targets of anti-Hu antibodies.  Across these 19 samples, 20 unique nELAVL 
peptides were identified. While the majority (>80%) of enriched peptides were attributed 
to ELAVL4 (HuD).  For the purpose of visualization, all nELAVL peptides from each 
sample were aligned to the most common isoform of ELAVL4 (accession 
NP_001311142.1), shown in Figure 2.5A.  
A majority (>90%) of the significantly enriched nELAVL peptides converged upon 
on a 17-residue sequence at AA positions 276-294 of ELAVL4, a sequence which is 
also common to variants of ELAVL2 and ELAVL3 (Figure 2.5B). The human peptidome 
PhIP-Seq library contained 18 peptides covering at least 10-residues of this short 
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sequence, reflecting the large number of published isoforms in the NCBI Protein 
database for these highly spliced and studied proteins. Due to this redundancy, rpK and 
fold-change calculations were attenuated by as much as two orders of magnitude as 
individual peptide counts were distributed across multiple sequences containing the 
same epitope. To account for this, the analysis was re-run treating all 18 peptides 
containing this short sequence as a single entity, the anti-Hu “signature.” This resulted 
in the detection of an additional 8 samples from 4 patients yielding significant 
enrichment of the signature sequence. Notably, a single patient (patient 26) enriched 
only a single peptide in both serum and CSF derived from the N-terminus of ELAVL2. 
The peptide is unique to ELAVL2 isoforms that had only been computationally predicted 
at the time of library design. These isoforms have since been confirmed experimentally 
and recognized as isoform c (accession NP_001338384.1).40 Importantly, none of 50 
healthy, de-identified, patient sera samples yielded significant enrichment of nELAVL-
derived peptides.  
The convergent 17-residue signature sequence common to the majority of 
patient samples lies within a functionally significant hinge region between two RNA 
binding domains (RRM2 and RRM3) and may contain nuclear localization and export 
sequences responsible for control of subcellular localization and neuronal 
differentiation.41 Though exon and isoform naming conventions vary in the literature, this 
region is used to distinguish unique splice variants of ELAVL2, ELAVL3, and ELAVL4 
(sv1, sv2, sv3) based on their inclusion or exclusion of relevant exons, specifically those 
commonly referred to as exons 6 and 7a. The identified motif terminates at the exon 
6/7a junction (Figure 2.5B). The majority of patient samples preferentially enriched 
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peptides that span the exon 6/7 junction, but do not include 7a, strongly suggesting that 
the binding determinants for the anti-Hu antibodies lie within this critical 17-residue anti-
Hu signature region. 
To further characterize the precise determinants of antibody binding, a new deep 
mutational scanning phage library was designed, encoding all possible single point 
mutants across the 17-residue signature motif (oligo design files available at 
https://github.com/derisilab-ucsf/PhIP-PND-2018). Samples from patients 01 and 38 
were profiled by deep-mutational scanning PhIP-seq, as they represented the samples 
with the most and least complex peptide representation at this region, respectively. At 
each position, the fold-change enrichment of each amino acid substitution against an 
AG-only IP and relative to the abundance of the reference sequence is shown in Figure 
2.5C, providing a landscape of the mutational tolerance at each residue. Examination of 
mutations that result in STOP codons (denoted by * in figure) are particularly 
informative, revealing the minimal sequence length required for antibody binding. 
Patient 01 antibodies required a minimal epitope containing residues up to and including 
positions 245-255 (QAQRFRLDNLL) with a shorter subsequence (QRFRLDNLL) being 
least tolerant of mutation. Patient 38’s antibodies appear to target a closely overlapping 
motif, RLDNLLN-AYG, with residues downstream not influencing peptide enrichment.  
In light of this refined anti-Hu signature sequence, patient 01’s original PhIP-Seq 
data was re-analyzed using GLAM2 (Gapped Local Alignment of Motifs) to identify 
enriched motifs. Of the 36 peptides identified as significant in both replicates, 34 (94%) 
share a short, 7-residue motif, identical to the RLDxxLL identified by the mutational 
scanning approach. These include 16 peptides that were not derived from nELAVL 
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genes, demonstrating that the dominant epitope in patient 01 is present in many 
unrelated protein sequences and explains the majority of peptides derived from non-
nELAVL enriched genes. The biological significance of promiscuous binding to 
unrelated proteins harboring this motif is unknown. 
 
2.3.8 Consensus motif contains subsequences with predicted and 
experimentally demonstrated T-Cell Antigenicity 
	
Examination of the refined anti-Hu signature motif and the full ELAVL4 sequence 
using the IEDB suite of sequence analysis tools (Figure 2.9) suggests that the motif has 
low predicted probability of being a linear B cell epitope (Bepipred 2.0). The motif does, 
however, contain several sequences predicted to have high affinity for major 
histocompatibility complex type 1 (MHC-I) alleles (A1, A2, and A3 supertypes) and high 
prediction scores for MHC processing and presentation, with two predicted proteasomal 
cleavage sites flanking the region at amino acid positions 246 and 264. Interestingly, 
peptides derived from this region have previously been identified as anti-Hu T cell 
antigens.42 Indeed, peptides containing this exact motif have been shown to bind with 
high affinity to HLA-A1 (RLDNLLNMAY) and HLA-A2/B18 (NLLNMAYGV) and also to 
activate autologous CD8+ T cells obtained from Hu-positive patients.43 
For paraneoplastic autoimmune diseases, the question of how immune tolerance 
is broken in the absence of new mutations remains to be addressed adequately. 
Selective exclusion of exons during expression in the thymus has been previously 
shown in mouse models as a possible route to break tolerance.44  In the case of the 
anti-Hu ELAVL family, splice variants have been previously shown to be controlled by a 
concentration-dependent autoregulatory mechanism wherein ELAVL proteins bind to 
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AU-rich elements on nascent transcripts, protecting them from splicing and exclusion.45 
Therefore, it may be possible that protein levels in the thymus during the development 
of central tolerance might fail to reach the requisite levels, resulting in exclusion of 
certain exons which in turn could affect processing and presentation. To further 
investigate this speculation, publicly available RNAseq datasets derived from bulk and 
sorted murine thymus and thymic medullary epithelial cells (mTECs) were examined. 
While most datasets lacked sufficient nELAVL coverage necessary for analysis of splice 
variants, a single mTEC from a single cell RNAseq dataset contained >50X coverage 
across ELAVL4, revealing the exclusion of exon 7a (Figure 2.9).46 Comparatively, 
sorted murine hippocampal and cerebellar neurons show essentially even coverage 
across all exons.47,48  
To further investigate exon inclusion and exclusion of nELAVL splice variants 
during the development of central tolerance, amplicon libraries spanning exons 5, 6,7a 
and 7 were generated from cDNA libraries derived from sorted human fetal and bulk 
adult thymic epithelial cells. An average of 1 million 125-nt paired-end reads (in 
triplicate) were obtained from each amplicon library. Exon 7a was represented in <0.5% 
of all reads in both fetal and adult TECs, supporting the notion that certain nELAV 
exons, such as exon 7a, are largely excluded from thymic expression. Interestingly, 
exon 7a is adjacent to exon 6 containing the critical anti-Hu signature motif. Taken 
together, these data point to a potential mechanistic connection to central thymic 
tolerance whereby incomplete T cell tolerance to selective exons within nELAVL helps 
promote an autoantibody response against this region of the protein. 
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PhIP-Seq Identifies Additional Known and Potentially Novel Autoantigens 
	
Antigens, other than those classically thought to be anti-Hu or anti-Yo were also 
investigated.  Anti-CRMP5 (DPYSL5/CV-2) antibodies are a well-established clinical 
biomarker for SCLC and malignant thymoma and can be found together with anti-Hu 
antibodies in patients with a PND.49 Two of the anti-Hu patients (patients 51 and 52) 
had previously tested positive for anti-CRMP5 antibodies with a clinical assay (indirect 
immunofluorescence screening on mouse tissue substrate).50 This was corroborated by 
PhIP-Seq, with both patients’ CSF samples yielding significant enrichment of CRMP5 
peptides. Patient 51 showed enrichment of 3 overlapping sequences at the C-terminus 
of the protein (AA residues 481-564) while patient 52’s CSF enriched for two peptides 
spanning residues 73-217. Though not contiguous on the primary sequence, these 
regions of the protein are in contact on the surface of the published three-dimensional 
structure (Figure 2.6). 
 
2.3.9 Comparison to Healthy Sera Samples Identifies Potential Disease-
Associated Binding Signatures 
	
To further detect additional disease-associated antigens, the PND cohort was 
compared to the binding signatures derived from the sera of 50 de-identified healthy 
subjects, thus allowing detection of known or potentially novel antigens by virtue of their 
enrichment at levels significantly higher than the healthy. To simplify analysis and avoid 
assumptions about the congruence of specific peptide binding signatures across 
multiple patients, we collapsed the data to the gene-level and called a patient sample 
positive for a given gene if it yielded enrichment of any peptides for said gene in 2 or 
more samples/replicates. We compared the number of samples testing positive for each 
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gene in the PND groups vs the control and determined significance by Fisher’s Exact 
test. The most significant gene-disease associations (FDR <0.05) are listed in Table 
2.1. The full list of associations and healthy patient peptide counts are available at 
https://github.com/derisilab-ucsf/PhIP-PND-2018. 
 
2.3.10 Zic and Sox Family Enrichment  
	
Among proteins that were significantly enriched, many have been previously 
identified as serological markers of cancer. Antibodies to ZIC (Zinc Fingers of the 
Cerebellum) and SOX (SRY-related HMG-box) families of transcription factors have a 
well-established clinical association with SCLC and PND.51,52 Consistent with this fact, 
enrichment of peptides derived from the ZIC family (ZIC1, 2, 3, 4 and 5) was significant 
in 13/44 anti-Hu patients and 0/50 healthy controls (pFisher’s exact = 0.000017) while 19/44 
patients and 2/50 healthy controls tested positive for SOX family peptides (pFisher’s exact = 
0.000004). Though a majority of the peptides were derived from SOX1 and SOX2, the 
most common sequence, present in 13/19 patients with SOX reactivity, was a 34-
residue sequence common to SOX1, 2, 3, 14, and 21. ZIC and SOX were the two most 
highly correlated genes in the anti-Hu patient data, with 7/13 patients with ZIC reactivity 
also enriching for a concurrent SOX peptide. 
 
2.3.11 Novel PND/Cancer Associated Signatures in Anti-Yo Patients 
	
Beyond established PND and cancer-associated biomarkers, the data revealed 
several potentially novel disease-associated peptide binding signatures. After adjusting 
for multiple tests (Benjamini-Hochberg), PCM1 (Pericentriolar Material 1), SAP25 
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(Sin3A Associated Protein 25), ROBO4 (Roundabout Guidance Receptor 4), and 
MTMR14 (Myotubularin Related Protein 14) each show significant (padj <= 0.05) 
association with anti-Yo PND. Peptides derived from PCM1 showed the strongest 
association, with 24/36 anti-Yo patients and 0/50 healthy controls enriching a total of 7 
unique peptides (pFisher’s exact < 10-11). PCM-1 antibodies have been reported in cases of 
parainfectious acute cerebellar ataxia and autoimmune scleroderma, 53,54  but this is, to 
our knowledge, the first reported case of anti-PCM1 activity associated with Anti-Yo 
PND. Multiple peptides from SAP25 and ROBO4 were each identified in 15 patients (5 
patients concurrently) while a single peptide from MTMR14 was common to 10 anti-Yo 
patients and zero healthy control sera.  
 
2.4 DISCUSSION 
	
We have designed and implemented the most complex and comprehensive 
human PhIP-Seq library to date, encompassing the entire human proteome and 
including all known and predicted splice variants and isoforms in the NCBI Protein 
database. In an effort to better understand autoimmune neurological diseases, we 
screened patient CSF and serum samples from two common paraneoplastic 
neurological disorders, the anti-Yo and anti-Hu syndromes. We chose these diseases 
for several reasons. First, while their autoantigens have been previously identified, the 
high-resolution epitope mapping afforded by PhIP-Seq or similar methods has, to our 
knowledge, not yet been achieved. Second, we reasoned that the high degree of 
alternative splicing in these neuronal antigens would help us leverage the unique design 
of our library which includes all published and computationally predicted splice variants. 
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Third, as these diseases are associated with a robust anti-tumor immune response, we 
reasoned that patient samples would likely enrich for multiple autoantigens that could 
have disease relevance and would be missed by more limited and hypothesis-driven 
antibody assays.  
To our knowledge, the PhIP-Seq data from the anti-Yo patient cohort represent 
the highest-resolution epitope mapping of anti-Yo antigens to date. PhIP-Seq correctly 
identified the canonical anti-Yo antigens, CDR2 and CDR2L in 36/36 patients. This 
highly concordant result suggests that anti-Yo PND antibodies routinely bind linear 
epitopes without any requisite post-translational modifications (PTMs) or significant 
secondary or tertiary structure. In addition, CDR2L peptides were much more enriched 
than CDR2 peptides. Indeed, across all samples, phage expressing CDR2L peptides 
represented 21% of all phage sequenced, and these peptides were represented in the 
top 5 most significantly enriched sequences in > 80% of samples tested. While these 
data do not provide a quantitative measurement of antibody affinity (especially to the 
native form in vivo), they suggest that CD2RL is the immunodominant antigen in 
patients suffering from anti-Yo PND. This also supports previous studies arguing that 
the antibody responses to each protein are independent (i.e., not cross-reactive) and 
that CDR2L is the primary antigen.55  
Within the anti-Hu cohort, PhIP-Seq yielded significant enrichment of nELAVL 
peptides in 17/34 patients. Those patients that were positive for nELAVL peptides 
yielded a remarkably convergent antigenic signature, with antibodies binding a short 17-
residue sequence (QAQRFRLDNLLNMAYGVK) shared by ELAVL2, 3 and 4 but absent 
in ELAVL1. This short sequence lies at the junction of exons 6 and 7a in ELAVL4, and 
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high resolution deep mutational scanning followed by motif analysis led to a further 
refined signature motif sequence (RLDNLLNMAY) as most deterministic for antibody 
binding. We note that this short sequence has been previously characterized as a T cell 
epitope in anti-Hu patients.42,43 Regarding the anti-Hu patients that did not yield 
peptides from nELAVL genes, it may be the case that the autoimmune antibodies in 
these patients may require specific secondary and tertiary conformations, somatic 
mutations, or PTMs not emulated by our peptide library.   
Interestingly, our analysis of publicly available RNAseq datasets and our own 
amplicon sequencing of human thymic epithelial cells reveals that exon 7a, immediately 
adjacent to our identified motif, is absent in >99% of ELAVL4 transcripts in the thymus 
but abundant in specific neuronal subtypes and brain regions in mice. While 
investigation of exon exclusion in the thymus and the mechanisms underpinning 
autoimmunity are beyond the scope of this initial survey, we speculate that the absence 
of these short exons during the development of central tolerance could potentially 
influence the rise of autoreactive T lymphocytes when the full-length protein is 
encountered in the CNS or expressed by peripheral tumors. Further, exclusion of exons 
bearing proteasomal cleavage sites (as with exon 7a) could bias MHC processing and 
presentation. Lineages of B cells with B cell receptors specific for ELAVL4 isoforms 
containing these excluded exons could presumably be maintained and expanded 
through interactions with CD4+ T cells specific for this short sequence when displayed 
on the surface of a B cell acting in its capacity as an antigen presenting cell. Such a 
collaborative process and mechanism is in keeping with previous studies examining 
autoimmune dymelinating disease and Nova2 PND.44,56  
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A major advantage of unbiased proteomic approaches like PhIP-Seq is the ability 
to interrogate patient samples for multiple antigens simultaneously, enabling high-
throughput antigen-antigen and antigen-disease associations. By comparing the PND 
patient data with a collection of 50 healthy sera run on our platform, we identified 
several known and potentially novel antigens and/or biomarkers associated with each 
disease; most notably, ZIC and SOX family genes in the anti-Hu patients and PCM-1 
and SAP25 in the anti-Yo cohort. The biological and clinical significance of these novel 
associations remain unknown. The clinical data on the specific cancer diagnosis and 
detailed neurologic phenotyping for each patient was not available for this study, and 
thus precludes analyses contrasting tumor type and particular neurologic deficits with 
the patient-level peptide binding signatures. Much like transcriptomic analyses, specific 
sets of correlated or biologically related antigens may provide researchers and clinicians 
with insight into yet undiscovered or previously unmeasurable cellular processes. We 
speculate, for example, that antibody binding signatures to endogenous, intracellular 
and normally inaccessible antigens reflect an immune process related to clearance of 
intracellular debris following apoptosis of tumor cells during the onco-immune 
response.57 The preponderance of ZIC and SOX related peptides in our anti-Hu cohort 
and their high levels of expression in SCLC, for example, supports the hypothesis that 
patient antibodies are providing a snapshot of the interior of tumor cells.15 The potential 
value of such biomarkers may only be realized after hundreds or thousands of patient 
samples have been run and correlated with higher-resolution disease phenotypic 
datasets that include long-term clinical outcomes and tumor transcriptional profiling.  
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This validation study confirms and extends the comprehensive nature of PhIP-
Seq peptidome libraries for the purpose of identifying novel autoantigens in patient 
groups. Ultimately, as comprehensive, proteome-wide serological screens are more 
widely adopted and replace conventional candidate-based approaches, we expect the 
diagnostic, prognostic, and research potential of such assays to be fully realized.  
Indeed, the third most common category of autoantibody-mediated causes of 
encephalitis belongs to patients with unidentified autoantigens that have defied 
identification by more conventional methods. 2  Furthermore, high-resolution datasets 
characterizing the co-occurrence of specific antigens and antigenic determinants to 
specific diseases, symptoms, and clinical outcomes may ultimately serve to identify 
early biomarkers and may even stratify patient outcomes and inform treatment 
decisions. Finally, higher resolution epitope mapping and analysis of antigenic 
signatures across multiple patients should better inform the currently incomplete models 
describing onco-immunologic processes and the loss of self-tolerance underpinning the 
rise of PND and autoimmune disease in general. 
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2.5 MATERIALS AND METHODS 
	
2.5.1 Computational Design of Library 
	
As a basis for the library, all human sequences in the NCBI protein database 
(Nov 2015) including all splicing isoforms and computationally predicted coding regions 
were downloaded. Full length sequences were clustered on 99% sequence identity 
(CD-HIT v4.6)30 to remove duplicate and partial sequences before computationally 
dividing them into 49 amino acid peptides using a 24 AA sliding window approach 
starting at the N-terminus. As such, each peptide shared a 25-residue overlap with the 
one preceding it on the primary protein sequence. Peptides encoding the final 49-
residues at the C-terminus were substituted when the final sliding window resulted in 
shortened or truncated sequences (proteins not evenly divisible by 49). The resulting 
peptides were further clustered/collapsed on 95% identity such that such that peptides 
with 2 or fewer amino acid differences were combined by randomly choosing one 
representative sequence. 
Amino acids sequences were converted to nucleotides using preferred E. coli 
codons (Table 2.2) and relevant restriction sites (EcoRI, HindIII, BamHI, XhoI) removed 
with synonymous mutations to facilitate cloning. To enable amplification from 
synthesized oligo pools, 21 nt universal priming sites were added to the 5’ and 3’ ends 
of each oligo. These sequences also serve to encode STREP and FLAG tag sequences 
(after addition of terminal codons by PCR) that allow for downstream assessment of 
proper, in frame cloning. The resulting library consists of 731,724 unique 189mer 
oligonucleotide sequences encoding 49AA human peptides flanked by 8AA STREP and 
FLAG sequences after amplification with appropriate primers. 
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2.5.2 Cloning into T7 Select vector 
	
ssDNA oligonucleotides were commercially synthesized in three separate pools 
by Agilent Technologies (Santa Clara, CA). Oligos were amplified by PCR primers 
adding relevant EcoRI and HindIII restriction sites. 200 pg of DNA (108 molecules per 
reaction across 50 reactions) was used as a template for each PCR reaction:  
Reagent Vol. (μl) Concentration 
Input DNA library 1 200 pg/μl 
Platinum HiFi master mix 10 5X 
Forward Primer* 
(adds EcoR1 site) 
2 10 μM 
Reverse Primer* 
(adds HindIII site) 
2 10 μM 
H2O 35 - 
 
*primer design: 
 
forward:  CTACGAATTCCTGGAGCCATCCGCAGTTCG 
reverse: CTACAAGCTTCTTATCATCGTCGTCCTTGTAGTC 
 
Thermocycling Conditions: 
Temperature (°C) Time (mm:ss) # cycles 
98 02:00 1 
98 00:30 
25 68 00:30 
72 00:30 
72 05:00 1 
4 Hold - 
 
 
PCR products were column cleaned (Zymo DNA clean and concentrator, Zymo 
Research, Irvine, CA) and eluted in 20 μl H2O. DNA was then subject to restriction 
digestion under the following reaction conditions (incubated at 37 for 1 hour): 
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Reagent Vol. (μl) Concentration 
Cleaned PCR product (DNA) 10 200 ng/μl 
CutSmart buffer (NEB) 5 10X 
EcoRI HF (NEB) 2 20,000 U/ml 
HindIII HF (NEB) 2 20,000 U/ml 
H2O 31 - 
 
To minimize the proportion of truncations and deletion errors most commonly 
associated with commercial synthesis chemistries, digested fragments were size 
selected by agarose gel electrophoresis (Blue pippin 3% cassette (BDQ3010)) before 
ligation/cloning. 
 
2.5.3 Cloning and Packaging 
	
The digested oligonucleotides were cloned and packaged into competent phage 
following the T7 select cloning manual. The following reaction mix was incubated at 
room temperature for 15 minutes: 
 
Reagent Vol. (μl) Concentration 
Digested, size-selected DNA 1 6 ng/μl 
T7 Vector Arms (EMD) 3 500 ng/μl 
Quick Ligase Buffer (NEB) 5 2X 
Quick Ligase (NEB) 1 10,000 U/ml 
 
2 μl of the ligation reaction were added directly to 10 μl of T7 packaging extract (EMD) 
and allowed to incubate at room temperature for 2 hours. Reaction was quenched by 
adding 200 μl of chilled, sterile, LB. 24 separate 10 μl packaging reactions were carried 
out to ensure library complexity. Packaging efficiency was determined by plaque assay 
(as described in T7 Select Cloning Manual). 
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2.5.4 In vivo amplification 
	
BLT5403 E. coli cultures were grown to log phase (OD600 = 0.5),inoculated 
(0.001 MOI) with packaging reaction, and allowed to clarify (complete lysis) by 
incubating in 37 °C incubator (2-3 hours). BLT5403 carries an ampicillin-resistant 
plasmid expressing a wildtype gene 10A behind a T7 promoter. Phage produced in this 
strain carry 5-15 copies of the 10B capsid protein bearing the cloned fusion peptide. 
Lysates were cleared of debris by centrifugation at 4,000 rcf at 4 °C for 30 min before 
filtering through a 0.22 micron filter.  
 
2.5.5 Concentrating and Storing Phage Library 
	
Phage were precipitated by adding 1/5 volume 5x PEG/NaCl precipitation buffer 
(PEG-8000 20%, NaCl 2.5 M) and centrifuged at 13,000g for 60 minutes. Pellets were 
raised in 1/4 starting volume storage buffer (20 mM Tris-HCl, pH 7.5, 100 mM NaCl, 
6mM MgCl2).58 Stocks were titered by plaque assay and diluted/concentrated to ~1011 
pfu/ml. 
 
2.5.6 Immunoprecipitation 
	
All liquid handling steps were carried out on Biomek FX robotics platform 
(Beckman Coulter, Brea, CA). 96-well, full skirted, low profile PCR plates (BioRad Inc, 
Hercules ,CA) were incubated overnight with 180 μl IP blocking buffer (3% BSA, PBS-T) 
to prevent nonspecific binding. Blocking buffer was replaced with 150 μl of phage library 
(1011 pfu in storage buffer) and mixed with 2 μl patients CSF, patient sera diluted 1:50 in 
blocking buffer, or 2 ng commercial antibody and incubated O/N at 4°C. 
	
	
34	
Protein A and G magnetic beads (Dynabeads – Invitrogen, Carlsbad, CA) were 
mixed equally, washed three times by magnetic separation and resuspension in 
equivalent volumes of TNP-40 wash buffer (150 mM NaCl, 50 mM Tris-HCL, 0.1% NP-
40, pH 7.5). 10 μl of A/G bead slurry was added to each IP reaction (using wide bore 
pipette tips) and incubated for 1 hour at 4°C. Bead-antibody complexes were washed 
three times by magnetic separation, removal of supernatant and resuspension in 150 μl 
TNP-40 wash buffer. Subsequent to final wash, beads were re-suspended in 150 μl 
chilled LB and used to inoculate fresh E. coli cultures (400 μl at OD600 = 0.5) for in vivo 
amplification. Lysates were clarified by centrifugation at 3,000g (at 4 degrees) and 150 
μl removed/stored for NGS library prep or additional rounds of IP. 
 
2.5.7 NGS Library Prep 
	
Sequencing libraries were prepared from lysates with a single PCR reaction 
using multiplexing (MP) primers as follows: 
 
Reagent Vol. (μl) Concentration 
E. coli lysate 2 Diluted 1:50 
Phusion HF Buffer (NEB) 10 5X 
Forward MP Primer* 2.5 10 μM 
Reverse MP Primer* 2.5 10 μM 
dNTPs 1 10 mM 
Phusion Polymerase 0.5 1U/μl 
H2O 31.5 - 
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*Multiplexing Primer Design: 
Forward: 
AATGATACGGCGACCACCGAGATCTACAC[NNNNNNN]GGAGCTGTCGTATTCCAG
TCAGGTGTGATGCTC 
 
NNNNNNN = i5 index 
 
Reverse: 
CAAGCAGAAGACGGCATACGAGAT[NNNNNNN]GGTTAACTAGTTACTCGAGTGCG
GCCGCAAGC 
 
NNNNNNN  = i7 index 
 
Thermocycling conditions: 
Temperature (°C) Time (mm:ss) # cycles 
95 02:00 1 
95 00:30 5 
63 00:30 
72 01:00 
95 00:30 5 
60 00:30 
72 01:00 
95 00:30 10 
58 00:30 
72 01:00 
72 02:00 1 
4 hold - 
 
Libraries were cleaned and size selected by Ampure XP magnetic beads (0.8X 
volume, 40 μl) (Beckman Coulter, Pasadena, CA), eluted in 20 μl of nuclease-free water 
and quantified by Qubit (Thermo Fisher, Waltham MA) dsDNA high sensitivity 
fluorimeter. Sequencing was performed on either an Illumina HiSeq 2500 or 4000 using 
custom indexing and sequencing primers: 
 
 
	
	
36	
Read 1 sequencing primer: TCCTGGAGCCATCCGCAGTTCGAGAAA 
Read 2 sequencing primer: AAGCTTCTTATCATCGTCGTCCTTGTAGTC 
i7 indexing primer: GGCCGCACTCGAGTAACTAGTTAACC 
i5 indexing primer: CACCTGACTGGAATACGACAGCTCC 
 
2.5.8 Bioinformatic Analysis 
	
Reads were quality filtered, paired-end reconciled (PEAR v0.9.8),59 and aligned 
to a reference database of the full library (bowtie2 v2.3.1).60 Sam files were parsed 
using a suite of in-house analysis tools (Python/Pandas) and individual phage counts 
were normalized to reads per 100k (rpK) by dividing by the sum of counts and 
multiplying by 100,000. Peptide-level fold changes were calculated by dividing individual 
peptide rpK values with their expected abundance (mean rpK in mock IPs). For peptides 
never observed in any control IP, fold changes were calculated using the median rpK for 
all peptides derived from that gene in the mock IP. 
We identified in our control IP’s a set of the 100 most abundant peptides that also 
have a standard deviation less than their mean. This “internal control” set represented 
the most abundant and consistent phage carried along specifically by the protein-AG 
beads or other reagents, in absence of any antibody. We calculate a sample-specific 
scaling factor, defined as the ratio of median abundances (rpK) of these 100 peptides in 
our controls to their abundance in the given sample. Fold change values are the 
multiplied by their sample-specific scaling factor. These top 100 peptide sequences are 
available at https://github.com/derisilab-ucsf/PhIP-PND-2018.  
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To account for the bias introduced in the fold-change calculation stemming from 
under-represented peptides in the mock IP having inflated fold-changes despite only 
modest representation in an experimental IP, we normalize, within each experimental 
batch (defined as  all samples on a given 96-well plate - never less than 50 samples), 
fold-change values using a correction factor defined as the solution to a linear 
regression fit to the fold-change values as a function of their mean log2(rpK) in AG-only 
controls (Figure 2.8). Importantly, fold-change values are only corrected when the 
correction factor is positive (expected fold-change given the abundance in mock IPs is 
positive). We fit a normal distribution to the scaled and normalized values and assign p-
values by evaluating the survival function (1-CDF) at a given fold-change (Figure 2.8). 
To account for multiple tests, we calculate an adjusted p-value (p_adj) using the 
Benjamini-Hotchberg procedure, enforcing a false discovery rate (FDR) of 0.05.  
Peptides were reported as significant as those with a positive fold-change with a p_adj 
<= 0.05 in both replicates.   
 
2.5.9 Design of Hu Motif Mutational Scanning Library 
 
 Degenerate 112 nt oligos were designed encoding 24 amino acids 
(PLHHQAQRFRLDNLLNMAYGVKRLMKL) spanning the 17-residue motif 
(QAQRFRLDNLLNMAYGVK) identified in the PhIP-Seq data. A unique oligo containing 
a degenerate NNN codon at each position was ordered/synthesized (IDT, San Diego, 
CA). Sequences were flanked with relevant restriction sites (EcoRI, HindIII) to enable in-
frame cloning. Oligos were pooled in equimolar ratios and cloned following the 
manufacturer’s protocol in the T7 Select Cloning Manual. Phage libraries were 
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subjected to 3 rounds of immunoprecipitation using patient antibodies (or AG beads 
alone) following the standard PhIP-Seq protocol described above. Final phage 
populations were sequenced with an average of ~2M 150 base paired-end reads on an 
Illumina MiSeq. Reads were quality filtered, reconciled/merged (PEAR),59 and translated 
to amino acid sequences. At each position, the antibody binding preference was defined 
as the log2(fold-change) of each amino acid substitution versus AG-only controls and 
relative to the endogenous/reference residue, quantified accordingly: 
 
Binding preference =  
(log2(Paa,j)Ab – log2(Paa,j)AG ) – (log2(Pwt,j)Ab – log2(Pwt,j)AG) 
where: 
Paa,j = proportion of reads with specific amino acid substitution (aa) at position j 
Pwt, j= proportion of reads with wildtype sequence (wt) at position j 
 
The mutational tolerance was then defined as the mean binding preference at each 
position. 
 
2.5.10 ELAVL4 amplicon sequencing from bulk thymus and human TECs 
	
Sorted TECs were isolated from human thymus obtained from 18- to 22-
gestational-week specimens under the guidelines of the University of California San 
Francisco Committee on Human Research. Tissue was washed, cut into small pieces 
using scissors, and gently mashed using the back of a syringe to extract thymocytes. To 
isolate TECs, remaining tissue pieces were digested at 37 °C using medium containing 
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100 μg/ml DNase I (Roche, Belmont, CA) and 100 μg/ml LiberaseTM (Sigma-Aldrich, St. 
Louis, MO) in RPMI. Fragments were triturated through a 5-ml pipette after 6 and 12 
min to mechanically aid digestion. At 12 min, tubes were spun briefly to pellet 
undigested fragments and the supernatant was discarded. Fresh digestion medium was 
added to remaining fragments and the digestion was repeated using a glass Pasteur 
pipette for trituration. Supernatant from this second round of digestion was also 
discarded. A third round of enzymatic digestion was performed using digestion medium 
supplemented with trypsin–EDTA for a final concentration of 0.05%. Remaining thymic 
fragments were digested for another 30 min or until a single cell suspension was 
obtained. The cells were moved to cold MACS buffer (0.5% BSA, 2 mM EDTA in PBS) 
to stop the enzymatic digestion. Following digestion, TECs were enriched by density 
centrifugation over a three-layer Percoll gradient with specific gravities of 1.115, 1.065 
and 1.0. Stromal cells isolated from the Percoll-light fraction (between the 1.065 and 1.0 
layers) were washed in MACS buffer. For surface staining, cells were blocked using a 
human Fc Receptor Binding Inhibitor Antibody (eBioscience, San Diego, CA) and 
incubated on ice for 30 min with the following antibodies: 
 
PE anti-human Epcam (HEA-125) (Miltenyi 130-091-253) - dilution 1:50 
Alexa Fluor 488 anti-human CD45 (HI30) (BioLegend 304017) - dilution 1:100 
 
Epcam+ CD45- DAPI- cells were sorted using a FACS AriaII (BD Biosciences, 
San Jose, CA) directly into TRIzol LS (ThermoFisher Scientific, South San Francisco, 
CA). The aqueous phase was extracted using the manufacturer's instructions followed 
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by RNA isolation using the RNeasy micro kit (QIAGEN, Redwood City, CA). RNA was 
reverse transcribed using iScript cDNA synthesis kit (Bio-Rad, Emeryville, CA). 
RNA samples from whole fetal and adult human thymus were purchased from 
Agilent (Santa Clara, CA) and Clontech (Mountain View, CA). RNA was reverse 
transcribed using iScript cDNA synthesis kit (Bio-Rad, Emeryville, CA). 
Amplicon libraries spanning the relevant exons were generated using the 
following primers: 
 
ELAVL4_fwd: GAACCGATTACTGTGAAGTTTGCCAAC 
ELAVL4_rev: GTAGACAAAGATGCACCACCCAGTTC 
 
PCR products were purified using the QIAGEN Gel Extraction kit and library 
construction was conducted on the quantified DNA using the NEBNext® Ultra™ DNA 
Library Prep Kit (New England Biolabs, Ipswich, MA). The final library was sequenced 
using a MiSeq with single-end, 300-base reads. 
 
2.5.11 Motif Discovery 
	
The redundant and overlapping nature of our library design presents some 
potentially confounding issues with existing motif discovery software packages 
leveraging hidden Markov models (HMMs) to identify significantly represented 
subsequences and motifs in a collection of sequences or strings. Highly redundant and 
replicate sequences as an input dataset confound or overwhelm the motif finding 
algorithms, often resulting in the most significant motifs reported as those in the 
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overlapping regions of adjacent peptides. To counter this, we manually curated patient 
results to eliminate sequences with >50% identity. We then iteratively searched each 
set of results for peptides with 10 or more identical sequential residues and chose as a 
representative sequence, that with the higher enrichment score (lowest adjusted p-
value). These curated datasets were examined by the researchers before being 
analyzed for motifs by GLAM2, part of the meme-suite software package.61  
 
2.5.12 Clinical PND Antibody Confirmation 
  
Confirmation of anti-Yo and anti-Hu activity in patient samples was performed in 
the Mayo Clinic Neuroimmunology Laboratory with CLIA and New York State approved 
methodology. Briefly,  patient samples (serum/CSF) were tested on a mouse composite 
tissue slide with an indirect immunofluorescence assay for IgG binding corresponding to 
the anti-Hu or anti-Yo pattern, as previously described.39 The results were confirmed 
with western blot analysis on rat cerebellum preparations.    
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2.6 FIGURES 
	
	
	
Figure 2.1 - Design and Characterization of Library. A.) All human protein isoforms, variants, 
and computationally predicted coding regions were downloaded from the NCBI Protein database. 
Full length sequences were clustered on 99% sequence identity (CD-HIT v4.6) to remove 
duplicate and partial sequences. Each protein was computationally divided into 49 amino acid 
peptides using a 24 AA sliding window. Redundant or duplicate sequences were removed by 
further clustering on 95% sequence identity. The resulting 731,724 sequences were synthesized 
and cloned into the T7 select vector (Millipore, Burlington, MA). B.) Assessment of the library 
quality before (blue) and after (yellow) cloning and packaging. 
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Figure 2.2 - Validation of library by commercial antibody IP's. Phage library was subjected to 
three rounds of selection by polyclonal commercial antibodies to GFAP and GPHN. A.) Replicates 
show high correlation of gene-level counts for IPs performed on separate days. Final libraries are 
dominated by the commercial antibody target. The GPHN antibody also consistently enriched a 
single peptide from chromogranin A (CHGA). B.) Scatterplots of peptide-level enrichments show 
18 unique GFAP peptides and 4 GPHN peptides were identified as antibody binders (red 
markers). Peptides sharing a motif with both GPHN and CHGA (white, see D). C.) Alignment of 
GFAP peptides to the full-length protein reveals two distinct regions of antibody affinity 
corresponding to regions of high solvent exposure and B cell antigenicity as predicted by IEDB 
Tools Emini surface exposure and Bepipred algorithms. D). Motif analysis of the significant 
peptides in the GPHN IP reveal a short, discontiguous motif shared by 144 significantly enriched 
peptides in the final population (from 94 unique genes/proteins), including the most abundant 
CHGA peptide. The motif is highlighted on the crystal structure of GPHN (top) and peptides 
sharing this motif are marked by a white circle in B. 
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Figure 2.3 - Anti-Yo representative results. A.) Representative data from 3 patients 
demonstrating the robust enrichment of CDR2/CDR2L peptides. CDR2/CDR2L peptides were the 
top 5 most abundant peptides in 44/51 samples. B.) While CDR2/CDR2L peptides represented 
21% of all phage, CDR2L enrichment is more pronounced and complex (more unique peptides 
per sample) than CDR2. 
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Figure 2.4 - Anti-Yo epitope mapping. Normalized coverage of each samples’ significant 
CDR2L peptides aligned to the full-length gene (divided into 5 amino acid bins). Patient binding 
signatures vary, though a majority converge on residues 322-346. B.) Patient antibodies 
targeting CDR2L bind to regions of least homology with CDR2, suggesting the antibody 
responses to each protein are independent. C.) Epitope map showing normalized peptide 
coverage across the full length CDR2 sequence. Patient antibodies enrich for peptides primarily 
restricted to the first 100 amino acids at the N terminus.   
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Figure 2.5 - Anti-Hu epitope mapping. A.) Antibody binding signatures for samples that enriched 
nELAVL peptides. A majority of patients show a markedly convergent binding preference for a 
short 17-residue sequence at the exon 6/7a junction of ELAVL4. B.) Mean fold-change values for 
peptides spanning the unique regions defining ELAV4 splice variants and those from ELAVL2 
and ELAVL3, indicating lack of enrichment beyond the exon 6/7a junction. C.) Mutational scan 
using smaller phage library with all possible point mutations at each location spanning the motif 
highlighted in (B). Mutational tolerance is calculated for each position, defined as the fold-change 
over unselected (AG-bead only IP) relative to the reference sequence. Most telling are the 
mutations encoding stop codons (denoted *) that reveal patient 01’s antibodies require a minimal 
sequence up to residues 255 (RLDDNLL) with the subsequence QRFRLDNLL least amenable to 
mutation. Patient 38’s antibodies bind to residues up to and including position 260 
(RLDNLLNMAYGV), with highest affinity for RLDNLLN-AYG. 
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Figure 2.6 - Patient 01 samples dominated by ELAV motif.  Immunodominant nELAVL motif 
in Patient 01 CSF sample is that identified by mutational scanning. The short sequence, 
dominated by RLDxLL is present in 34 of the 36 peptides identified in both replicates. Apart from 
nELAVL proteins, the patient’s antibodies enrich for peptides from 16 additional genes containing 
the motif. The biological consequences of such promiscuous autoantibody binding are unknown. 
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Figure 2.7 - Anti-CRMP5 epitope mapping. Two anti-Hu PND patient (patients 51 and 52) CSF 
samples also enriched CRMP5 peptides. CRMP5 is a well-established clinical biomarker for 
SCLC and malignant thymoma and anti-CRMP5 antibodies are often found concurrently with anti-
Hu antibodies in patients with a PND. Though the peptides identified in each patient were 
discontiguous on the primary amino acid sequence, they are in close proximity in the 3D protein 
structure of CRMP5 at the region surrounding the C-terminus and the interface of the CRMP5 
homodimer. 
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Figure 2.8 - Scaling and normalizing peptide fold-change values. A scaling factor, defined as 
the ratio of median rpK values of the top 100 mock IP AG bead-binding phage (see Methods), 
was multiplied by the normalized peptide count for a given experimental sample. A.) Plotting the 
scaling factor vs the proportion of an experimental sample’s final phage population present at or 
above the top 0.1% of rpK shows that samples dominated by a phage scale more dramatically. 
B.) Linear regression of scaled fold-change values to peptide representation in mock IPs. 
Intuitively, peptides with low abundance in the control IPs have higher calculated fold changes 
despite low rpK in the final population. Fold-change values were normalized by subtracting the 
solution to the fitted line when the expected fold-change was greater than 0. The resulting 
shifted/normalized fold changes (C.) are centered around 0 and normally distributed (D).  
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Figure 2.9 - PhIP-Seq Identifies short exon in ELAVL4 excluded in thymus. A.) Exon map of 
ELAVL4. B.) Normalized PhIP-Seq coverage from all positive patients shows preferential binding 
of antibodies to exon 6. Exon 6 has low predicted B cell antigenicity but high prediction of MHC 
processing and presentation by IEDB tools Bepipred algorithm.62 C.) Exon 6 contains top scoring 
MHC-I binding prediction score defined by Roberts, et al.43 Analysis of publicly available datasets 
reveals exon 7a is excluded from transcripts in murine mTECs but included in mouse hippocampal 
and cerebellar neuron scRNAseq datasets. D.) Amplicon sequencing of human TEC cDNA 
corroborates exclusion of exon 7a in the thymus.  
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2.7 TABLES 
	
	
	
PND Antigen 
Unique 
Peptides # samples p fisher’s exact p adj Relevant Clinical Associations PND Healthy PND Healthy 
Hu 
SOX 
family 28 1 19 2 4.0 x 10
-06 0.01 
NSCLC, SCLC, 51 
esophageal and bladder 
cancer,63 
ZIC family 25 0 13 0 1.7 x 10-05 0.01 SCLC,
64 ovarian and 
breast cancer65,66 
Yo 
PCM1 7 0 24 0 2.1 x 10-12 1.5 x 10-9 
Parainfectious ataxia,53 
scleroderma,54 
glioblastoma67 
SAP25 16 0 15 0 3.6 x 10-07 2.0 x 10-4 
Ovarian cancer,68 
 promyelocytic  
leukemia69 
ROBO4 4 1 15 1 4.1 x 10-06 1.8 x 10-3 
Breast cancer,70 
bladder cancer,71 
glioma72 
MTMR14 1 0 10 0 8.7 x 10-05 3.2 x 10-2 none discovered 
	
Table 2.1 - Significant antigen-disease associations. Comparison	of	PhIP-Seq	patient	binding	
data	 to	 a	 collection	 of	 50	 healthy	 serum	 samples	 reveals	 known	 and	 potentially	 novel	 PND-
binding	 signatures.	 Genes	 showing	 significant	 associations	 after	 correcting	 for	 multiple	 tests	
(p_adj,	Benjamini	Hotchberg).		SOX	and	ZIC	family	transcription	factors	are	well	established	SCLC	
cancer	biomarkers,	and	these	antibodies	are	often	associated	with	PND,	particularly	anti-Hu.	In	
the	anti-Yo	cohort,	PhIP-Seq	enriched	for	PCM1,	SAP25,	ROBO4,	and	MTMR14.		
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Amino	Acid	 Codon	 	 Amino	Acid	 Codon	
A GCG  L CTG 
C TGC  N AAC 
B GAT  Q CAG 
E GAA  P CCG 
D GAT  S AGC 
G GGC  R CGT 
F TTT  U TGC 
I ATT  T ACC 
H CAT  W TGG 
K AAA  V GTG 
J CTG  Y TAT 
M ATG  X GCT 
   Z GAA 
	
Table 2.2 - Preferred E. coli codons used in library design. 
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Chapter 3  
 
Metagenomic next-generation sequencing for chronic 
meningitis: a case series 
 
3.1 ABSTRACT 
	
Identifying infectious causes of subacute and chronic meningitis can be 
challenging. Enhanced, unbiased diagnostic approaches are needed. Here, we assess 
the utility of metagenomic deep sequencing (MDS) of cerebrospinal fluid (CSF) in 
diagnostically challenging cases of subacute and chronic meningitis. We present a case 
series of patients in whom metagenomic next-generation sequencing (mNGS), 
supported by a statistical framework leveraging mNGS sequencing data from non-
infectious patients and environmental controls, successfully identifies the responsible 
pathogen. mNGS identified parasitic worms, fungi and viruses in seven subjects: Taenia 
solium (n=2), Cryptococcus neoformans, human immunodeficiency virus-1, Aspergillus 
oryzae, Histoplasma capsulatum, and Candida dubliniensis. Evaluating mNGS data with 
a weighted z-score based scoring algorithm effectively separated bona fide pathogen 
sequences from spurious environmental sequences. Prioritizing metagenomic data 
findings with a scoring algorithm greatly clarified data interpretation and highlights the 
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difficulties attributing biological significance to organisms present in control samples 
used for metagenomic sequencing studies. 
 
3.2 INTRODUCTION 
	
Subacute and chronic meningitis is diagnostically challenging given the wide 
range of potential infectious, autoimmune, neoplastic, paraneoplastic, parameningeal 
and toxic causes.73,74 Securing a final diagnosis can require weeks or months of testing 
or remain unsolved, necessitating empiric treatment approaches that may be ineffective 
or even harmful. 
Unlike traditional testing for specific microbes or categories of infection, 
metagenomic and metatranscriptomic next-generation sequencing (mNGS) of 
cerebrospinal fluid (CSF) or brain tissue screens for all potential CNS pathogens, and 
can identify novel or unexpected pathogens.75,76,77,78,79,80,81,82 Multiple computational 
algorithms and pipelines have been developed to identify microbial sequences in mNGS 
datasets rapidly.83,84,85  However, mNGS data requires careful analysis to determine 
which, if any, of the identified microbes represent a true pathogen versus environmental 
contamination, and failure to make this distinction has resulted in spurious disease 
associations with organisms later determined to be laboratory contaminants.86,87,88 
This chapter describes a straightforward statistical approach to analyze mNGS 
data leveraging an extensive database of water-only controls (n=24) and surplus CSF 
samples (n=94) obtained from patients with clinically-adjudicated non-infectious 
neurologic diagnoses including autoimmune, neoplastic, structural and 
neurodegenerative etiologies (“control cohort”). This statistical approach quantifies the 
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uniqueness of observing a particular microbe in a patient sample at a given level of 
abundance (at multiple taxonomic levels) by comparison to its mean level of abundance 
across the control cohort. Here we report the utility of this statistical framework for 
identifying microbial pathogens in seven challenging cases of subacute or chronic 
meningitis, as well as for analyzing publicly-available data from recent mNGS infectious 
diagnostic and brain microbiota studies.89,10,90 
 
3.3 RESULTS 
 
The seven study subjects ranged in age from 10 to 55 years old, and three (43%) 
were female. Additional clinical details are listed in Table 3.1. In each case, the 
causative pathogen was identified within the top two scoring microbes identified by our 
algorithm (Figure 3.2). Across the seven study subjects, the mean of reported taxa was 
reduced by 87% (range 41-99%) if taxa with a combined score of zero or less were 
removed (i.e., average of 307 (range 11-1,313) taxa before filtering and 53 (range 1-297 
after filtering). 
  
3.3.1 Case Descriptions 
 
Taenia solium 
 
Participant 1 was a 29 year-old man from Nicaragua with headache and diplopia. 
CSF examination revealed an opening pressure of >50 cm, 66 WBC/mm3 (89% 
lymphocytes, 4% neutrophils, 4% monocytes and 3% eosinophils), 1 RBC/mm3, total 
protein 43 mg/dL (normal range 15-50 mg/dL), and glucose 27 mg/dL (normal range 40-
70 mg/dL). Contrast-enhanced brain magnetic resonance imaging (MRI) revealed 
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enhancement of the basilar meninges and several cranial nerves (Figure 2.3A). 
Although serum cysticercosis antibody was positive, there were no cysts or 
calcifications on brain MRI. The low CSF glucose, basilar meningitis, positive tuberculin 
skin test, positive tuberculosis interferon-gamma release assay, and his high-risk 
country of origin prompted empiric treatment for Mycobacterium tuberculosis (TB) 
meningitis. He improved clinically over the next three weeks but then worsened, 
requiring multiple lumbar punctures (LPs), MRIs and hospitalizations over the next year. 
Subsequent CSF samples showed worsening lymphocytic pleocytosis, persistently low 
glucose and elevated protein. Neuroimaging demonstrated persistent basilar meningitis 
and development of communicating hydrocephalus, again without cysts. His incomplete 
clinical response was initially attributed to treatment noncompliance, but after he 
worsened despite directly observed TB therapy, multi-drug resistant TB was suspected. 
After his fourth clinical decline (including discussion of ventriculoperitoneal shunt 
placement for worsening hydrocephalus) he was readmitted to the hospital for a new 
diagnostic work-up. Empiric therapy was broadened to include anti-helminthic 
treatment. CSF was submitted for research-based mNGS. The mNGS data 
demonstrated no sequences aligning to mycobacterial species. However, 58,789 
unique, non-human read pairs aligned to the genus Taenia (Table 3.2), with the vast 
majority specifically mapping to the Taenia solium genome (Figure 3.2). A CSF 
specimen that had been sent concurrently for fungal 18s rRNA polymerase chain 
reaction (PCR) unexpectedly amplified the Taenia solium 18s rRNA gene, and CSF 
cysticercosis IgG antibody was positive. A FIESTA (Fast Imaging Employing Steady-
state Acquisition) sequence protocol was included for the first time on the brain MRI, 
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and this revealed tangled hypointensities in the basilar cisterns, most prominently 
involving the prepontine cisterns with extension into the right internal auditory canal. 
After eight months of anti-helminthic treatment, he clinically improved to baseline except 
for a residual action tremor.   
            Participant 2 was a 34 year-old woman who had immigrated to the United States 
from El Salvador 13 years prior. She presented with nine months of right-sided 
headache, left facial numbness, right pulsatile tinnitus and recurrent loss of 
consciousness. Brain MRI showed hydrocephalus and right anterior temporal lobe and 
pre-pontine cysts (Figure 3.3B). CSF examination revealed an opening pressure of 36 
cm, 115 WBC/mm3 (1% neutrophils, 31% monocytes, 46% lymphocytes, 21% 
plasmacytoid lymphocytes and 1% eosinophils), 2 RBC/mm3, glucose <10 mg/dL and 
total protein 89 mg/dL. After her CSF and serum cysticercosis IgG antibody returned 
positive, she was treated with albendazole and prednisone for more than one month. 
However, she developed worsening neck pain, and a repeat CSF exam showed 
elevated intracranial pressure, pleocytosis with a new eosinophilia, undetectable 
glucose and elevated protein, raising concern for an alternative diagnosis. Her CSF 
mNGS data contained 569 read-pairs (Table 3.2) aligning to the genus Taenia (Figure 
3.2). She was treated with dual anti-helminthic therapy with adjunctive glucocorticoids 
and had an excellent clinical response. 
 
Cryptococcus neoformans 
	
Participant 3 was a 52 year-old man with a history of migraine and HIV-1 
infection diagnosed in 2013 (viral load detectable but <40 copies/mL; CD4 count 20 
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cells/mm3). He also had a history of injection drug use (IDU), hepatitis C virus infection, 
Staphylococcus aureus endocarditis, and syphilis. He presented with agitation, 
confusion and ataxia. Because of his prior S. aureus bacteremia, syphilis, history of 
migraine and immunosuppressed state, the differential diagnosis remained broad. 
mNGS on CSF identified 839 unique read pairs (Table 3.2) that aligned to the genus 
Cryptococcus, essentially all of which aligned to Cryptococcus neoformans. Serum 
cryptococcal antigen was positive at a titer of > 1:160, and CSF cryptococcal antigen 
was positive at a titer of > 1:1280. Numerous fungal yeast forms were present in the 
CSF, and Cryptococcus neoformans grew in the CSF fungal culture. Except for hepatitis 
C virus, no other pathogens were identified via CSF mNGS (Figure 3.2) or by standard 
diagnostic assays. He clinically improved on additional anti-cryptococcal therapy. 
 
Recurrent Encephalopathy in the Context of Known HIV-1 Infection 
	
Participant 4 was a 55 year-old man with treatment-naïve HIV-1 infection 
diagnosed eight years prior. He presented to the Emergency Department with two 
weeks of confusion, decreased verbal output, as well as several months of cough, 
intermittent night sweats and weight loss; his CD4 count was 6 cells/mm3. Brain MRI 
showed bilateral, confluent and non-enhancing white matter T2 hyperintensities. CSF 
examination showed 0 WBC/mm3, 0 RBC/mm3, glucose 34 mg/dL, and total protein 93 
mg/dL. CSF mNGS testing revealed more than 136,000 unique read pairs aligning to 
HIV-1 (Table 3.2, Figure 3.2). The full-length HIV-1 genome was assembled using 
paired read iterative contig extension (PRICE) v1.1.2.91 The mean total read coverage 
across the HIV-1 genome was 3,991. No reads to JC virus, herpesviruses or fungal 
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pathogens were observed. His clinical course was consistent with HIV-1 dementia, and 
no other opportunistic CNS infection was identified with extensive testing. 
 
Aspergillus oryzae 
	
Participant 5 was a 32 year-old man who presented to the Emergency 
Department with seven months of episodic dizziness, diplopia, headache, left facial 
numbness and weakness. He had a history of IDU and hepatitis C virus infection. HIV-1 
testing was negative. Brain MRI revealed contrast enhancement in the left pons, middle 
cerebellar peduncle, and right posterior aspect of the pituitary infundibulum. A computed 
tomography (CT) angiogram revealed multiple areas of focal stenosis in the posterior 
circulation. CSF examination showed 95 WBC/mm3 (77% lymphocytes, 13% 
neutrophils, 6% monocytes, 4% reactive lymphocytes), 0 RBC/mm3, total protein of 61 
mg/dL, glucose of 45 mg/dL. Bacterial and fungal cultures were negative for CSF and 
blood. He was treated for a suspected autoimmune process with glucocorticoids. Two 
weeks later the patient’s symptoms worsened. Repeat brain MRI revealed a new 
punctate infarct in the right thalamus. Repeat CSF examination showed worsening 
pleocytosis with a neutrophilic predominance. Bacterial cultures were negative. CSF 
Aspergillus galactomannan returned at 11.26 (positive > 0.5). A third CSF exam showed 
an even greater pleocytosis of 343 WBC/mm3 (63% lymphocytes, 20% neutrophils, 15% 
monocytes, 2% reactive lymphocytes). CSF Aspergillus galactomannan was again 
elevated at 7.23. CSF mNGS returned 857 read-pairs mapping to Aspergillus spp. 
(Table 3.2) with the majority of the reads mapping to Aspergillus oryzae. CSF 18s rRNA 
PCR also returned positive for Aspergillus spp., and the CSF 1,3-ß-D-glucan was 
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elevated. No cause of immunocompromise was identified, and no systemic aspergillus 
infection was identified. Treatment with oral voriconazole was initiated, and his 
hydrocephalus was treated with ventriculoperitoneal shunting. He was then lost to 
follow-up. 
 
Histoplasma capsulatum 
	
Participant 6 was a 10 year-old girl with an early childhood spent in Indiana and 
Ohio, who presented in Seattle with six months of back pain and 10 days of progressive 
left facial droop, headache, neck pain, and vomiting. She had severe meningismus on 
exam. Brain and spinal MRI showed diffuse leptomeningeal enhancement. CSF 
examination revealed 68 WBC/mm3 (33% neutrophils and >30% monocytes), 98 
RBC/mm3, glucose <20 mg/dL, and total protein 292 mg/dL. Empiric therapy was 
initiated for bacterial meningitis, herpes simplex virus, and endemic mycoses. She 
developed respiratory failure and paraplegia. Repeat neuroimaging demonstrated new 
pontine infarcts and non-enhancing, longitudinal T2 hyperintensities throughout the 
cervicothoracic cord. Her therapy was broadened to cover TB meningitis. Ultimately, 
CSF fungal culture and 18s rRNA PCR revealed Histoplasma capsulatum. mNGS 
showed 33 read-pairs mapping to Histoplasma capsulatum (Table 3.2, Figure 3.2). After 
two months of treatment, she could ambulate but continues to have profound left 
hearing loss, facial weakness and neurogenic bladder. 
 
Candida dubliniensis 
	
Participant 7 was a 26 year-old woman with an initially undisclosed history of IDU 
who presented with one year of atraumatic lower back pain followed by subacute 
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development of saddle anesthesia and left foot drop. On MRI, she had a loculated, rim-
enhancing collection extending from the top of the lumbar spine anteriorly compressing 
the conus medullaris against the posterior wall, in addition to diffuse leptomeningitis 
involving the entire spinal cord and brainstem (Figure 3.3C-E). Cisternal CSF showed 
126 WBC/mm3 (67% neutrophils, 22% lymphocytes and 11% monocytes), 4 RBC/mm3, 
total protein of 105 mg/dL, and a glucose of 40 mg/dL. Extensive infectious disease 
diagnostic studies were unrevealing, and 11 weeks later the patient underwent lumbar 
meningeal biopsy. The pathology revealed non-inflammatory, dense fibrous tissue, and 
no microbes were identified. Consistent with the pathology that did not show evidence 
of active infection in sample that was biopsied, 18s rRNA and 16s rRNA PCRs, and 
mNGS of biopsy tissue did not reveal evidence of infection. 18s rRNA PCR of CSF was 
also negative. Three months later the patient became wheelchair-bound. Repeat 
cisternal CSF showed 700 WBC/mm3 (81% neutrophils, 16% lymphocytes, 2% 
monocytes and 1% eosinophils), 2 RBC/mm3, total protein of 131 mg/dL and a glucose 
of 44 mg/dL. CSF mNGS revealed 68 read-pairs mapping to Candida spp. (Table 3.2) 
with 61 of the 68 pairs mapping to Candida dubliniensis with 99-100% identity. A CSF 
1,3-ß-D-glucan assay was 211 pg/mL (<80 pg/mL), whereas the serum 1,3-ß-D-glucan 
assay had been repeatedly normal. Repeat CSF 18s rRNA and 16s rRNA PCRs were 
negative. The patient is being treated with combination anti-fungal therapy with mild 
clinical improvement, normalization of her CSF profile (including a negative CSF 1,3-ß-
D-glucan) and decreasing leptomeningeal enhancement on MRI. Two of the previous 
three reported cases of Candida dubliniensis meningitis were in patients with a history 
of IDU.92,93,94 
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3.3.2 Background Signature of Reagent and Environmental Contaminants 
	
Examination of nucleotide alignments generated by non-templated water-only 
controls (n=24) and non-infectious CSF samples (n=94) revealed 4,400 unique 
bacterial, viral, and eukaryotic genera. This microbial background signature was 
predominated (>70%) by consistent proportions of bacterial taxa, primarily the 
Proteobacteria and Actinobacteria classes (Figure 3.4) representing common soil, skin, 
and environmental flora previously reported as laboratory and reagent contaminants.88 
To determine if these common microbial contaminants may have been misclassified as 
pathogens in previously published studies, we examined publicly available data from 
two cases of meningoencephalitis for which a possible infection was identified by 
mNGS.90 In each case, neither organism (Delftia acidovorans, Elizabethkingia) was 
present at levels significantly greater than the mean of our background dataset of water-
only and non-infectious CSF controls. We then examined data from a study aiming to 
characterize the “brain microbiome” and correlate brain dysbiosis to disease.89,10 The 
abundance of the purported brain microbiota reveal distributions that are well within the 
observed variance we observe within our set of background water-only, non-templated 
controls (Figure 3.4). Of note, the authors of the brain microbiome study did not deep 
sequence water controls as they could not generate measurable quantities of DNA after 
reverse transcription-PCR (RT-PCR). The presence of environmental contaminants is 
due in part to low amounts of input RNA, which is frequently the case with acellular CSF 
samples, combined with the PCR amplification cycles necessary to generate a 
sequencing library. To assess this explicitly, we performed an RNA doping experiment 
(Figure 3.5) on a water sample and an uninfected CSF sample from which there was no 
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detectable cDNA after RT-PCR. The mNGS libraries made from the water and CSF 
samples had 9.4% and 7.6% unique, non-human sequences, respectively. The 
proportion of non-human sequences dropped dramatically after spiking in only 20 
picograms of RNA of a known identity suggesting that non-human environmental 
sequences are particularly problematic for low input nucleic acid samples, which is often 
the case for CSF.  
 
3.4 DISCUSSION AND CONCLUSIONS 
	
We present seven diagnostically challenging cases of subacute and chronic 
meningitis in which mNGS of CSF identified a pathogen, including a case of 
subarachnoid neurocysticercosis that defied diagnosis for one year, the first case of 
CNS vasculitis caused by Aspergillus oryzae, and the fourth reported case of Candida 
dubliniensis meningitis. A straightforward statistical model leveraging a large mNGS 
dataset obtained from water-only, non-templated controls and patients with a variety of 
non-infectious neuroinflammatory syndromes correctly prioritized the pathogens. Larger, 
prospective studies are needed to determine the clinical utility of this approach for 
reducing the number of false positives and false negatives. 
CSF mNGS has the potential to overcome several limitations of conventional 
CNS infectious disease diagnostics. First, the inherent risks of brain and/or meningeal 
biopsy make CSF mNGS a particularly attractive and less invasive diagnostic option for 
patients with suspected CNS infection. Second, the large number of neuroinvasive 
pathogens that cause subacute or chronic meningitis makes it logistically challenging 
and cost-prohibitive to order every possible neuro-infectious diagnostic test using a 
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candidate-based approach. Third, some assays lack sensitivity in the context of 
impaired immunity or acute infection (e.g., West Nile virus serology), can be slow to 
yield results (e.g., mycobacterial and fungal cultures) or may fail to differentiate between 
active infection and prior exposure (e.g., cysticercosis antibody or the interferon-gamma 
release assay test for M. tuberculosis). 
The unbiased nature of mNGS makes the datasets inherently polymicrobial and 
complex. Thus, statistical scoring and filtering is essential to enhance the ability to 
discriminate between insignificant contaminants and true infectious organisms. Our 
algorithm correctly prioritized etiologic pathogens in these seven clinically-confirmed 
cases of infectious meningitis despite the fact that the pathogens ranged widely with 
regard to their absolute abundance (33-136,000 sequence read pairs) and the 
proportion of the non-human sequences (0.89-92.7%) that they comprised (Table 3.2).  
In addition, we analyzed a recently published clinical mNGS dataset to highlight 
that a thoroughgoing profile of the microbes present in water-only controls and non-
infectious CSF reinforces the skepticism with which the authors described a possible 
infection in one subject with Delftia acidovorans (patient 2) and in another subject with 
Elizabethkingia (patient 7) (Figure 3.4). Furthermore, such a database could help 
improve the accuracy of microbiome studies, especially for body sites historically 
considered sterile in which rigorous controls are necessary to establish that observed 
microbial sequences represent microbiota vs environmental contaminants 
(Supplementary Figure 1C).10,90 This problem appears to be particularly acute in 
samples like CSF whose sub-nanogram levels of input RNA/DNA require unbiased 
molecular amplification steps before enough material is available for sequencing 
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applications. Indeed, the addition of only 20 picograms of purified RNA to a CSF sample 
was sufficient to suppress the majority of non-CSF reads deriving from the water and 
reagents (Figure 3.5). While amplifying the input signal increases the sensitivity of the 
assay, it also often over-represents the signature of contaminating taxa unique to a 
given laboratory, experimenter, or reagent lot.86,88 These results provide a cautionary 
note and underscore the need for appropriate controls to aid in interpretation.  
We expect larger databases of patient mNGS results will only enhance the ability 
to discriminate between irrelevant sequences and legitimate pathogens and permit 
more rigorous and probabilistic models for pathogen ranking and reporting. We present 
here one empirically derived system for prioritizing results, based on the read count 
weighted by standard z-scores. Given the sensitivity of NGS-based approaches, we 
anticipate individual laboratories will need to develop their own dynamic reference 
datasets to control for contaminants that are relevant to the particular time, place, and 
manner in which the biological samples are being analyzed.  
mNGS represents an increasingly rapid and comparatively low cost means of 
screening CSF in an unbiased fashion for a broad range of human pathogens using a 
single diagnostic test. While this selected case series is not appropriate to measure the 
performance characteristics in a prospective cohort, a recently completed 
demonstration project sponsored by the State of California 
(http://www.ciapm.org/project/precision-diagnosis-acute-infectious-diseases), may also 
prove to be helpful in supporting the exclusion of CNS infection when a co-infection is 
suspected in an immunosuppressed patient (as illustrated by our cases with C. 
neoformans and HIV-1) or when a non-infectious cause, such as an autoimmune 
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condition, is clinically favored. On this basis, we foresee the eventual replacement of 
many single-agent assays performed in reference labs with a unified mNGS approach. 
 
3.5 MATERIALS and METHODS 
	
Participants were recruited between September 2013 and March 2017 as part of 
a larger study applying mNGS to biological samples from patients with suspected 
neuroinflammatory disease. The seven participants had subacute or chronic  
leptomeningitis with or without encephalitis. An etiologic diagnosis was not known by 
the researchers at the time of study enrollment. If an infection was made by traditional 
means before mNGS testing was complete (participants 3, 5 and 6), the researchers 
performing mNGS remained blinded to the diagnosis. The cases were referred from the 
University of California, San Francisco (UCSF) Medical Center (n=2), Zuckerberg San 
Francisco General Hospital (n=2), Cleveland Clinic, University of Washington and 
Kaiser Permanente. The UCSF Institutional Review Board (IRB) approve the study 
protocol, and participants or their surrogates provided written informed consent. 
Treating physicians were informed about research-based mNGS results under an IRB-
approved reporting mechanism.  
 
3.5.1 mNGS Protocol 
	
mNGS was performed on total RNA extracted from surplus CSF (250-500 µL), 
and one subject also had mNGS performed on total RNA extracted from <50 mg of 
snap frozen, surplus tissue from a lumbar meningeal biopsy. Samples were processed 
for mNGS as previously described.77,79 The non-human sequence reads have from 
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each sample have been deposited at the National Center for Biotechnology Information 
(NCBI) Sequence Read Archive, BioProject (PRJNA338853).   
  
3.5.2 Bioinformatics and Statistical Analysis 
	
Paired-end 125-150 base pair (bp) sequences were analyzed using a previously 
described rapid computational pathogen detection pipeline consisting of open source 
components (Figure 1).77,79 Unique, non-human sequences were assigned to microbial 
taxonomic identifiers (taxids) based on nucleotide (nt) and non-redundant (nr) protein 
alignments. To distinguish putative pathogens from contaminating microbial sequences 
derived from skin, collection tubes, lab reagents, or the environment, a composite 
background model of metagenomic data was employed. This model incorporated 24 
water controls and 94 CSF samples from patients with non-infectious diagnoses, 
including 21 chronic meningitis with or without encephalitis cases. Data were 
normalized to unique reads mapped per million input reads (rpM) for each microbe at 
the species and genus level. Using this background dataset as the expected mean rpM 
for a given taxid, standard Z-scores were calculated for each genus (gs) and species 
(sp) in each sample based on the results from both the nt and nr database searches. 
Thus, there are four z-scores reported for each sample: Znt,sp, Znt,gs, Znr,sp, Znr,gs. To 
prioritize reporting of the most unique (i.e., unexpected) taxa in each sample, the 
significance of each microbial species was mapped to a single value with the following 
empirically-derived formula: 
 
Score = Znt,sp (Znt,gs (rpMnt)) + Znr,sp (Znr,gs (rpMnr)) 
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Here, the rpM values are scaled by both the z-score for the species and the genus. If 
both z-scores are negative, the product remains negative. The maximum z-score is 
arbitrarily capped at 100. This product is calculated for alignments to both the nt and nr 
databases and summed. The top-ranked taxa were considered with respect to the 
clinical context of the patient. Microbes with known CNS pathogenicity that could cause 
a clinical phenotype concordant with the clinical presentation were considered potential 
pathogens and were confirmed by standard microbiologic assays, as described in the 
brief case histories herein. 
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3.6 FIGURES  
	
Figure 3.1 - Diagram of a rapid computational pipeline. Values for participant 1 are shown as 
an example. The cerebrospinal fluid sample obtained from participant 1 yielded 13,141,550 million 
read-pairs, which were then subjected to removal of human reads by spliced transcripts alignment 
to a reference (STAR, version 2.4.2),95 quality control filtering (PriceSeqFilter, version 1.1.2),91 
compression of duplicate reads (CD-HIT-DUP, version 4.6.4-2015),96 removal of low-complexity 
sequences by filtering for high Lempel-Ziv-Welch (LZW)81 compression ratios, a second round of 
removal of human reads (Bowtie 2, version 2.2.4),60 alignment to the National Center for 
Biotechnology Information (NCBI) nucleotide (nt) database (GMAP/GSNAP, version 2015-12),98 
alignment to the NCBI nonredundant (nr) protein database (RAPSearch2, version 2.23),99 and 
statistical calculation and taxonomy reporting using PHP/MySQL, version 5.5.53. The entire 
computational pipeline was completed in 19.6 min using a single high-end server (32 core, Intel 
Xeon E5-2667 v3 with a 3.2-GHz processor and 768 Gb of RAM). NA indicates not applicable. 
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Figure 3.2 - Ranked Results of Statistical Scoring. Strip plot of normalized species significance 
scores for microbial taxa (colored circles) in each participant sample (row). In 6 of 7 samples, the 
neurologic infection (orange circles) is ranked as the most significant by our approach. In 
participant number 5, Aspergillus oryzae is ranked second behind GB virus C, a likely concurrent 
infection unassociated with the clinical presentation (blue circle). Microbes likely representing 
environmental contaminants are also shown (gray circles). 
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Figure 3.3 - Selected Neuroimaging.  A.) Axial T1-weighted brain magnetic resonance image 
(MRI) with contrast enhancement demonstrating basilar meningitis (arrowheads) in a 28-year-
old man (participant 1) with neurocysticercosis identified by metagenomic next-generation 
sequencing (mNGS). B.) Axial T2-weighted brain MRI demonstrating right anterior temporal 
lobe and prepontine cysts (arrowheads) in a 34-year-old woman with neurocysticercosis 
(participant 2) identified by mNGS. C-E.) Axial T1-weighted MRI with contrast enhancement 
showing basilar meningitis (C [arrowhead]), and a sagittal T1-weighted lumbar spine MRI 
showing a loculated rim-enhancing collection extending from the top of the lumbar spinal cord 
anteriorly and compressing the conus medullaris against the posterior wall without (D) and with 
(E, arrowheads) contrast in a 26-year-old woman with Candida dubliniensis meningitis 
(participant 7) identified by mNGS. 
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Figure 3.4 - Background signature of reagent and environmental contaminants. A.) The 10 
most abundant genera identified water-only and reagent controls (n=24). 10 bacterial taxa 
account for ~50% of all non-human (viral, bacterial, fungal, and selected eukaryotes) sequences 
in the control data. B.) Organized at the class-level, four classes of bacteria (α-proteobacteria, β-
proteobacteria, γ- proteobacteria, Actinobacteria) represent >80% of the sequences in the 
wateronly and reagent controls. C.) The proportion of Delftia acidovorans sequences (dotted line 
at 0.93) CNS infection identified by mNGS is concordant with the expected mean of our control 
dataset (0.97). Similarly, the proportion of Elizabethkingia sequences (dotted line) in another 
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possible infectious case from the same report is significantly lower than the mean abundance in 
our control dataset. D.) Comparison of the observed variance of the four classes of bacteria (B) 
to publicly available data from a recent report10 on microbiota in healthy and multiple sclerosis 
patient brain specimens suggests that the relative abundances of each taxa in the brain 
specimens are within the observed variance of our background dataset.  
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Figure 3.5 - RNA doping experiment. Comparison of the percent non-human sequences (y-
axis) found in water (column 1) and a cerebrospinal fluid (CSF) control (column 2) and the 
decrease in the percent non-human sequences found with increasing amounts of spiked RNA of 
a known identity (columns 3-7). Added RNA was generated by T7 in vitro transcription from a 
cloned luciferase reporter gene, purified, quantified, and spiked into the CSF at the indicated 
amounts. These data suggest that common environmental contaminants are present at low 
picogram quantities, and the addition of only 20 pg is sufficient to suppress the majority of reads 
not derived from the CSF.  
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Chapter 4  
 
Depletion of Abundant Sequences by Hybridization 
(DASH): using Cas9 to remove unwanted high-
abundance species in sequencing libraries and 
molecular counting applications 
 
4.1 ABSTRACT 
	
Next-generation sequencing has generated a need for a broadly applicable 
method to remove unwanted high-abundance species prior to sequencing. We 
introduce DASH (Depletion of Abundant Sequences by Hybridization). Sequencing 
libraries are ‘DASHed’ with recombinant Cas9 protein complexed with a library of guide 
RNAs targeting unwanted species for cleavage, thus preventing them from consuming 
sequencing space. We demonstrate a more than 99% reduction of mitochondrial rRNA 
in HeLa cells, and enrichment of pathogen sequences in patient samples. We also 
demonstrate an application of DASH in cancer. This simple method can be adapted for 
any sample type and increases sequencing yield without additional cost. 
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4.2 INTRODUCTION 
	
The challenge of extracting faint signals from abundant noise in molecular 
diagnostics is a recurring theme across a broad range of applications. In the case of 
RNA sequencing (RNA-Seq) experiments specifically, there may be several orders of 
magnitude difference between the most abundant species and the least. This is 
especially true for metagenomic analyses of clinical samples like cerebrospinal fluid 
(CSF), whose source material is inherently limited,75 making enrichment or depletion 
strategies impractical or impossible to employ prior to library construction. The presence 
of unwanted high-abundance species, such as transcripts for the 12S and 16S 
mitochondrial ribosomal RNAs (rRNAs), effectively increases the cost and decreases 
the sensitivity of counting-based methodologies. 
The same issue affects other molecular clinical diagnostics. In cancer profiling, 
the fraction of the mutant tumor-derived species may be vastly outnumbered by wild-
type species due to the abundance of immune cells or the interspersed nature of some 
tumors throughout normal tissue. This problem is profoundly exaggerated in the case of 
cell-free DNA/RNA diagnostics, whether from malignant,100,101 transplant,102 or fetal 
sources,103,104 and relies on brute force counting by either sequencing or digital PCR 
(dPCR)105 to yield a detectable signal. For these applications, a technique to deplete 
specific unwanted sequences that is independent of sample preparation protocols and 
agnostic to measurement technology is highly desired 
CRISPR (clustered regularly interspaced short palindromic repeats) and Cas 
(CRISPR associated) nucleases, such as Cas9, function in bacterial adaptive immune 
systems to remove infecting phage DNA from the host without harm to the bacteria’s 
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own genome. The CRISPR-Cas9 system has attained widespread adoption as a 
genome editing technique.106,107,108,109 When coupled with single guide RNAs (sgRNAs) 
designed against targets of interest, Streptococcus pyogenes Cas9 binds to 3’ NGG 
protospacer adjacent motif (PAM) sites and produces double-stranded breaks if the 
sgRNA successfully hybridizes with the adjacent target sequence (Figure 4.1). In vitro, 
Cas9 may be used to cut DNA directly, in a manner analogous to a conventional 
restriction enzyme, except that the target sequence (outside of the PAM site) may be 
programmed at will and massively multiplexed without significant off-target effects. This 
affords the unique opportunity to target and prevent amplification of undesired 
sequences, such as those that are generated during next-generation sequencing (NGS) 
protocols. 
In this chapter, we have exploited the unique properties of Cas9 to selectively 
deplete unwanted high-abundance sequences from existing RNA-Seq libraries. We 
refer to this approach as Depletion of Abundant Sequences by Hybridization (DASH). 
Employing DASH after transposon-mediated fragmentation (or adapter ligation) but prior 
to the following amplification step (which relies on the presence of adaptor sequences 
on both ends of the fragment) prevents amplification of the targeted sequences, thus 
ensuring they are not represented in the final sequencing library (Figure 4.1b). We show 
that this technique preserves the representational integrity of the non-targeted 
sequences while increasing overall sensitivity in cell line samples and human 
metagenomic patient samples. Further, we demonstrate the utility of this system in the 
context of cancer detection, in which depletion of wild-type sequences increases the 
detection limit for oncogenic mutant sequences. The DASH technique may be used to 
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deplete specific unwanted sequences from existing Illumina sequencing libraries, PCR 
amplicon libraries, plasmid collections, and virtually any other existing collection of DNA 
species. 
Existing specific sequence enrichment techniques — such as pull-down 
methods, 103,110,111,112 amplicon-based methods,101,113 molecular inversion 
methods,114,115,116 COLD-PCR,117 competitive allele-specific TaqMan PCR (castPCR),118 
and the classic method of using restriction enzyme digestion on mutant sites — can 
effectively enrich for targets in sequencing libraries,119 but these are not useful for 
discovery of unknown or unpredicted sequences. Brute force counting methods also 
exist, such as dPCR,101,105 but they are not easy to multiplex across a large panel of 
samples. While high-throughput sequencing of select regions can be highly multiplexed 
to detect rare and novel mutations, and barcoded unique identifiers can overcome 
sequencing error noise,120 it is costly since the vast majority of the sequencing reads 
map to non-informative wild-type sequences. A number of sequence-specific RNA 
depletion methods also currently exist. Illumina’s Ribo-Zero rRNA Removal Kit and 
Ambion’s GLOBINclear Kit pull rRNAs and globin mRNAs, respectively, out of total RNA 
samples using sequence-specific oligos conjugated to magnetic beads. RNAse H-based 
methods, such as New England BioLab’s NEBNext rRNA Depletion Kit similarly mark 
abundant RNA species with sequence-specific DNA oligos, and then subject them to 
degradation by RNAse H, which digests RNA/DNA hybrid molecules.121 These methods 
are all employed prior to the start of library prep, and are limited to samples containing 
at least 10 ng to 1 μg of RNA. DASH, in contrast, depletes abundant species after 
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complementary DNA (cDNA) amplification, and thus can be utilized for essentially any 
amount of input sample. 
 
4.3 RESULTS 
	
We demonstrate deletion of unwanted mitochondrial rRNA using DASH first on 
HeLa cell line RNA (Figure 4.2) and then on CSF RNA from patients with pathogens in 
their CSF (Figure 4.3), in order to increase sequencing bandwidth of useful data. 
Selection of rRNA sgRNA targets was based on examining coverage plots for standard 
RNA-Seq experiments on HeLa cells as well as on several patient CSF samples. 
Coverage of the 12S and 16S mitochondrial rRNA genes was consistently several 
orders of magnitude higher than the rest of the mitochondrial and non-mitochondrial 
genes (Figs. 4.2c and 4.3). We chose 54 sgRNA target sites within this high-coverage 
region of the mitochondrial chromosome, situated approximately every 50 bp over a 2.5 
kb region (Table 4.2). sgRNA sites are indicated by red arrowheads in Fig. 4.2B. 
sgRNAs for these sites were generated as described in the "Materials and methods" 
section. 
To calculate the input ratio of Cas9 and sgRNA to sample nucleic acid, we 
estimated (based on prior experience generating mNGS libraries from human samples) 
that 90% of each sample was comprised of the rRNA regions that we targeted; thus, our 
potential substrate makes up 4.5 ng of a 5 ng sample. This corresponds to a target site 
concentration of 13.8 nM in the 10 μL reaction volume. To assure the most thorough 
Cas9 activity possible, and given that Cas9 is a single-turnover enzyme in vitro,122 we 
used a 100-fold excess of Cas9 protein and a 1000-fold excess of sgRNA relative to the 
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target. Thus, each 10 μL sample of cDNA generated from a CSF sample contained a 
final concentration of 1.38 μM Cas9 protein and 13.8 μM sgRNA. In the case of HeLa 
cDNA, we used only 1 ng per sample, and therefore decreased the Cas9 and sgRNA 
concentrations by fivefold. However, since mitochondrial rRNA sequences represented 
only approximately 60% of the HeLa samples (compared with approximately 90% for 
CSF), the HeLa samples contained 150-fold Cas9 and 1500-fold sgRNA. To examine 
dose response, we processed additional 1 ng HeLa samples treated with 15-fold Cas9 
and 150-fold sgRNA. Both concentrations were done in triplicate (Figure 4.1). 
 
4.3.1 Reduction of unwanted abundant sequences in HeLa samples  
	
We first demonstrate the utility and efficacy of our approach using sequencing 
libraries prepared from total RNA extracted from HeLa cells. In the untreated samples, 
reads mapping to 12S and 16S mitochondrial rRNA genes represent 61% of all uniquely 
mapped human reads. After DASH treatment, these sequences are reduced to only 
0.055% of those reads (Figure 4.2). Comparison of gene-specific fragments per 
kilobase of transcript per million mapped reads (fpkm) values between treated and 
untreated samples reveals mean 82-fold and 105-fold decreases in fpkm values for 12S 
and 16S rRNA, respectively, in the samples treated with 150-fold Cas9 and 1500-fold 
sgRNA. Similarly, the samples treated with 15-fold Cas9 and 150-fold sgRNA show 30 
and 45-fold reductions in 12S and 16S fpkm values, respectively, indicating a dose-
dependent response to DASH treatment (Figure 4.1). 
 
 
	
	
84	
4.3.2 Enrichment of non-targeted sequences in HeLa samples 
	
This profound depletion of abundant 12S and 16S transcripts increases the 
available sequencing capacity for the remaining, untargeted transcripts. We quantify this 
increase by the slope of the regression line fit to the remaining genes, showing a 2.38-
fold enrichment in fpkm values for all untreated transcripts. An R2 coefficient of 0.979 for 
this regression line indicates strong consistency between replicates with minimal off-
target effects (Figure 4.2c). 
To confirm that our depletion was specific to only the targeted mitochondrial 
sequences, we calculated the changes in fpkm values across all genes in the treated 
and untreated samples and identified those genes that were significantly diminished (>2 
standard deviations) relative to their control values. To overcome issues with stochastic 
variation at low gene counts/fpkm, we eliminated those genes that, between the three 
technical replicates at each Cas9 concentration, showed standard deviations in fpkm 
values greater than 50% of the mean. All of the genes meeting this criterion were 
present at less than 15 fpkm. Of the remaining genes, only one non-targeted human 
gene, MT-RNR2-L12, showed significant depletion when compared with the un-treated 
samples (Fig. 4.2c). MT-RNR2-L12 is a pseudogene and shares over 90% sequence 
identity with a portion of the 16S mitochondrial rRNA gene. Out of the 24 sgRNA sites 
within the homologous region, 16 of them retain intact PAM sites in MT-RNR2-L12. Of 
these, seven have perfectly matching 20mer sgRNA target sites, and the remaining nine 
each have between one and four mutations (Figure 4.6). Depletion of this gene is, 
therefore, an expected consequence of our sgRNA choices. 
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4.3.3 Reduction of unwanted abundant sequences in CSF samples 
	
We next tested the utility of our method when applied to clinically relevant 
samples. In the case of pathogen detection in patient samples, the microbial transcripts 
are typically low in number and become greatly outnumbered by human host 
sequences. As a result, sequencing depth must be drastically increased to confidently 
detect such small minority sequence populations. We reasoned that depletion of 
unwanted high-abundance sequences from patient libraries could result in increased 
representation of pathogen-specific sequence reads. We thus integrated the DASH 
method with our in-house metagenomic deep sequencing diagnostic pipeline for 
patients with meningeal inflammation (i.e., meningitis) or brain inflammation (i.e., 
encephalitis) likely due to an infectious agent or pathogen. Figure 4.3 and Table 4.1 
summarize the results of this analysis. In all three cases, the DASHed and untreated 
samples have a similar number of reads (1.8–3.4 million), but DASHing reduces the 
number of duplicate reads, indicating an increase in library complexity.  
In the case of a patient with meningoencephalitis whose CSF was previously 
shown to be infected with the amoeba Balamuthia mandrillaris (patient 1),76 diagnosis 
was originally made by identification of a small fraction (<0.1%) of reads aligning to 
specific regions of the B. mandrillaris 16S mitochondrial gene. After DASH treatment, 
human mitochondrial 12S and 16S genes were reduced by more than an order of 
magnitude, and sequencing coverage of the B. mandrillaris 16S fragment increased 3.6-
fold. Notably, B. mandrillaris is a eukaryotic organism, yet depletion of the human 16S 
gene by DASH did not have off-target effects on the 16S B. mandrillaris mitochondrial 
gene. Similarly, patient CSF samples with confirmed Cryptococcus neoformans (fungus; 
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patient 2) and Taenia solium (pork tapeworm; patient 3) infections showed 2- and 3.9-
fold increases in coverage of the 18S genes of C. neoformans and T. solium, 
respectively, the detection of which was crucial in the initial diagnoses. The observed 
increases in relative signal can be translated into either a sequencing cost savings or a 
higher sensitivity that may be useful clinically for earlier detection of infections. 
 
4.3.4 Reduction of wild-type background for detection of the KRAS G12D 
(c.35G>A) mutation in human cancer samples 
	
Specific driver mutations known to promote cancer evolution and at times to 
make up the genetic definition of malignant subtypes are important for diagnosis and 
targeted therapeutics. In complex samples isolated from biopsies or cell-free body fluids 
such as plasma, wild-type DNA sequences often overwhelm the signal from mutant 
DNA, making the application of traditional Sanger sequencing challenging.100,101,123 For 
NGS, detection of minority alleles requires additional sequencing depth and increases 
cost. We reasoned that the DASH technique could be applied to increase mutation 
detection from a PCR amplicon derived from a patient sample. We chose to focus on 
depletion of the wild-type allele of KRAS at the glycine 12 position, a hotspot of frequent 
driver mutations across a variety of malignancies.124,125,126 This is an ideal site for DASH 
because all codons encoding the wild-type glycine residue contain a PAM site (NGG), 
while any mutation that alters that residue (e.g., c.35G>A, p.G12D) ablates the PAM site 
and is thus uncleavable by Cas9 (Figure. 4.4a). This will be true of any mutation that 
changes a glycine (codons GGA, GGC, GGG, and GGT) or a proline (codons CCA, 
CCC, CCG, and CCT) to any other amino acid. Furthermore, it is relevant to the 
ubiquitous C>T nucleotide change found in germline mutations as well as somatic 
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cancer mutations.127 Targeting of other mutations will likely be possible in the near 
future with reengineered CRISPR nucleases or those that come from alternative 
species and have different PAM site specificities.128,129 
The sequence of the sgRNA designed to target the KRAS G12D PAM site is 
listed in Table 4.2, as is the non-human sequence used for the negative control sgRNA. 
Both were transcribed from a DNA template by T7 RNA polymerase, purified, and 
complexed with Cas9 as described in the "Materials and methods" section. Samples 
were prepared by mixing sheared genomic DNA from a healthy individual (with wild-type 
KRAS genotype confirmed with dPCR) and KRAS G12D genomic DNA to achieve 
mutant to wild-type allelic ratios of 1:10, 1:100, and 1:1000, and 0:1. For each mixture, 
25 ng of a DNA was incubated with 25 nM Cas9 pre-complexed with 25 nM of sgRNA 
targeting KRAS G12D. This concentration is high relative to the concentration of target 
molecules, but empirically we found it to be the most efficient ratio. We hypothesize that 
this may be due to non-cleaving Cas9 interactions with the rest of the human 
genome,122 which effectively reduce the Cas9 concentration at the cleavage site. 
Samples were subsequently heated to 95 °C for 15 min in a thermocycler to 
deactivate Cas9 ("Materials and methods"). Droplet digital PCR (ddPCR) was used to 
count wild-type and mutant alleles using the primers and TaqMan probes depicted in 
Fig. 4.4a and described in the "Materials and methods" section. All samples were 
processed in triplicate. Samples incubated with or without Cas9 complexed to a non-
human sgRNA target show the expected percentages of mutant allele: approximately 10 
%, 1 %, and 0.1 % for the 1:10, 1:100, and 1:1000 initial mixtures respectively (Fig. 
4.4b). With addition of Cas9 targeted to KRAS, the wild-type allele count drops nearly 
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two orders of magnitude (purple bars in Fig. 4.4b), while virtually no change is observed 
in number of mutant alleles (blue bars). This confirms the high specificity of Cas9 for the 
NGG of the PAM site. 
With the addition of DASH targeted to KRAS G12, the percentage of mutant 
allele jumps from 10 % to 81 %, from 1 % to 30 %, and from 0.1 % to 6 % (Fig. 4.4c). 
This corresponds to 8.1-fold, 30-fold and 60-fold representational increases for the 
mutant allele, respectively. As expected, there was virtually no detection of mutant 
alleles in the wild-type-only samples both with and without DASH treatment (one droplet 
in one of three no DASH wild-type-only samples). 
 
4.4 DISCUSSION 
	
In this chapter I have described DASH, a technique that leverages in vitro Cas9 
ribonucleoprotein (RNP) activity to deplete specific unwanted high-abundance 
nucleotide sequences, which results in the enrichment of rare and less abundant 
sequences in NGS libraries or amplicon pools. 
While the procedure may be easily generalized, we developed DASH to address 
current limitations in metagenomic pathogen detection and discovery, where the 
sequence abundance of an etiologic agent may be present as a minuscule fraction of 
the total. For example, infectious encephalitis is a syndrome caused by well over 100 
pathogens ranging from viruses, fungi, bacteria and parasites. Because of the sheer 
number of diagnostic possibilities and the typically low pathogen load present in CSF, 
more than half of encephalitis patients never have an etiologic agent identified.130 We 
have demonstrated that NGS is a powerful tool for identifying infections, but as the B. 
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mandrillaris meningoencephalitis case demonstrates, the vast majority of sequence 
reads are “wasted” re-sequencing high abundance human transcripts. In this case, we 
have shown that DASH depletes with incredible specificity the small number of human 
rRNA transcripts that comprise the bulk of the NGS library, thereby lowering the 
required sequencing depth to detect non-human sequences and enriching the 
proportion of non-human (Balamuthia) reads in the metagenomic dataset. In this study, 
we have targeted mitochondrial rRNA species because we have consistently observed 
them to be the most abundant sequences in these CSF-derived RNA samples. For 
other types of tissues, alternative programming of DASH for removal of nuclear rRNA 
species or essentially any other abundant sequences would be warranted. 
In the case of infectious agents, it is possible to directly enrich rare sequences by 
hybridization to DNA microarrays or beads.110,131 However, these approaches rely on 
sequence similarity between the target and the probe and therefore may miss highly 
divergent or unanticipated species. Furthermore, the complexity and cost of these 
approaches will continue to increase with the known spectrum of possible agents or 
targets. In contrast, the identity and abundance of unwanted sequences in most human 
tissues and sample types has been well described in scores of previous transcriptome 
profiling projects,121 and therefore optimized collections of sgRNAs for DASH depletion 
are likely to remain stable. 
A number of methods for depleting ribosomal RNA from RNA-Seq libraries exist 
in the form of commercially available kits. We assert that DASH is equally effective or 
better than these methods on four metrics: (1) input requirements, (2) performance, (3) 
programmability, and (4) cost. These can be assessed based on information available 
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on company websites or in publications for three major competing techniques: Illumina’s 
Ribo-Zero and Thermo Fisher’s RiboMinus, which both use biotinylated capture probes 
for depletion; and New England Biolab’s NEBNext rRNA depletion kit, which uses 
RNAse H for depletion. 
 
4.4.1 Input requirements  
	
Illumina recommends 1 μg of total RNA as input for Ribo-Zero, but also has a 
low-input protocol requiring only 100 ng. ThermoFisher recommends 2–10 μg of total 
RNA for its standard RiboMinus protocol, and 100 ng to 1 μg for its Low Input 
RiboMinus Eukaryote System v.2. NEB recommends 10 ng to 1 μg total RNA input for 
the NEBNext rRNA Depletion Kit. The reason for these stringent amount requirements 
is that these three methods all deplete samples at the RNA stage. DASH, in contrast, 
avoids the need to delicately manipulate the original sample. Instead, DASH is 
employed after cDNA synthesis and library generation; thus, it can be performed on any 
library, without regards to starting total RNA amount, or the manner in which the library 
was constructed (tagmentation or otherwise). For scarce and precious samples, such as 
patient CSF, often less than 10 ng of total cDNA is available even after NuGEN Ovation 
amplification; prior to this work, no commercial depletion method was available for these 
samples. 
 
4.4.2 Performance  
	
All commercial rRNA depletion methods promise at least 85% reduction in reads 
of the sequences they target. Illumina states that the Ribo-Zero technique can achieve 
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between 85% and >99% reduction in the rRNA sequences it targets; RiboMinus states 
95–98 % reduction; and NEBNext states 95–99% reduction. Adiconis et al. compared 
several RNA-Seq methods and reported on many metrics, including depletion of rRNA 
sequences.121 Ribosomal RNA sequences comprised 84.7% of reads in their un-
depleted sample (100 ng total RNA from K-562 cells), while Ribo-Zero reduced this to 
11.3% (an 86.7% reduction), and RNAse H reduced it to 0.1% (a 99.9% reduction). In 
this paper, we show that DASH decreases the mitochondrial rRNA reads in HeLa total 
RNA from 61% to 0.055% (99.9% reduction). Adiconis et al. obtained similar numbers 
from 1 μg total RNA samples from formalin-fixed paraffin-embedded (FFPE) kidney 
tissue (78.2 % and 99.9 % reduction for Ribo-Zero and RNAse H, respectively) and 
pancreas tissue (73.0 % and 99.7 % reduction for Ribo-Zero and RNAse H, 
respectively). This is comparable to DASH reduction in three patient CSF samples 
(82.1%, 81.4% and 88.2% reduction). However, it is important to note again that 
Adiconis et al. used 1 μg total RNA from tissue samples, while the DASHed CSF 
samples consisted of only 5 ng of NuGEN Ovation-amplified cDNA (total RNA content in 
the original CSF samples was too low to accurately quantify). 
Another important measure of performance is maintenance of relative 
abundances of non-targeted sequences, such as the human transcriptome. Correlation 
coefficients for samples with and without DASH treatment ranged from R2 = 0.979 to 
0.994 in this study (Figures 4.2, Figure 4.6), slightly higher than those found by Adiconis 
et al. for all methods. 
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4.4.3 Programmability 
	
DASH can be adapted to target any sequence containing a PAM site; 
construction of new sgRNAs is facile and inexpensive (see "Materials and methods" 
section). Because it is employed after sequencing adapter addition, DASH’s utility is not 
limited to RNA-Seq; it can be applied to any library type. Examples include ATAC-Seq 
libraries, in which desired nuclear DNA is contaminated with a significant amount of 
mitochondrial DNA sequences, and microbiome sequencing, where it may be desirable 
to eliminate a particularly abundant species in order to better sample the underlying 
diversity. Since Ribo-Zero, RiboMinus and NEBNext are all proprietary kits, they cannot 
easily be re-programmed by the user to target other sites. 
 
4.4.4 Cost 
	
Based on current publicly available list prices of the most economical kit sizes, 
the per-sample costs (in US dollars) of the kits discussed here are $82.00 (Ribo-Zero 
Gold Kit H/M/R), $93.67 (RiboMinus Human/Mouse Transcriptome Isolation Kit) and 
$45.00 (NEBNext rRNA Depletion Kit H/M/R). In contrast, we calculate the cost of 
DASH at less than $4 per sample when Cas9 and T7 RNA polymerase are made in-
house — a very sensible solution for labs that are already spending large amounts of 
money on NGS. Where Cas9 production is not possible, DASH can still be carried out 
using commercially available Cas9 protein. 
DASH may also enhance the detection of rare mutant alleles that are important 
for liquid biopsy cancer diagnostics. Allelic depletion with DASH increases the signal 
(oncogenic mutant allele) to noise (wild-type allele) by more than 60-fold when studying 
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the KRAS hotspot mutant p.G12D. Other approaches for enriching lowabundance 
mutations exist, such as restriction enzyme digestion and COLD-PCR. However, these 
methods are limited when large mutation panels are required. Here we have described 
a single application for DASH in cancer, but the utility of this method will be fully realized 
by multiplexing large panels of mutation sites, using guide RNAs and PAM sites as a 
way to essentially create programmable restriction enzymes that can be used in a single 
pool. With the rapidly growing number of oncologic therapies that target particular 
cancer mutations, sensitive and non-invasive techniques for cancer allele detection are 
increasingly relevant for optimizing patient care.123 These same techniques are also 
becoming increasingly important for diagnosis of earlier stage (and generally more 
curable) cancers as well as the detection of cancer recurrence without needing to re-
biopsy the patient.100,112 
The potential applications of DASH are manifold. Currently, DASH can be 
customized to deplete any set of defined PAM-adjacent sequences by designing 
specific libraries of sgRNAs. Given the popularity and promise of CRISPR technologies, 
we anticipate the adaptation and/or engineering of CRISPR-associated nucleases with 
more diverse PAM sites.128,129,132 A portfolio of next-generation Cas9-like nucleases 
would further enable DASH to deplete large and diverse numbers of arbitrarily selected 
alleles across the genome without constraint. We envision that DASH will be 
immediately useful for the development of non-invasive diagnostic tools, with 
applications to low input samples or cell-free DNA, RNA, or methylation targets in body 
fluids.102,104,133,134,135,136,137 
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Many other NGS applications could also benefit from depletion of specific 
sequences, including hemoglobin mRNA depletion for RNA-Seq of blood samples and 
tRNA depletion for ribosome profiling studies.138 Depletion of pseudogenes or otherwise 
homologous sequences by small but consistent differences in sequences is also 
theoretically possible, and may serve to remove ambiguities in clinical high-throughput 
sequencing. Using DASH to enrich for minority variations in microbial samples may 
enable early discovery of pathogen drug resistance. Similarly, the application of DASH 
to the analysis of cell-free DNA may augment our ability to detect early markers of drug 
resistance in tumors.123 
 
4.5 CONCLUSIONS 
	
Here, we have demonstrated the broad utility of DASH to enhance molecular 
signals in diagnostics and its potential to serve as an adaptable tool in basic science 
research. While the degree of regional depletion of mitochondrial rRNA was sufficient 
for our application, the depletion parameters were not maximized: we used only 54 
sgRNA target sites out of about 250 possible S. pyogenes Cas9 sgRNA candidates in 
the targeted mitochondrial region. Future studies will explore the upper limit of this 
system while elucidating the most effective sgRNA and CRISPR-associated nuclease 
selections, which will likely differ based on target and application. Irrespective, depletion 
of unwanted sequences by DASH is highly generalizable and may effectively lower 
costs and increase meaningful output across a broad range of sequence-based 
approaches. 
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4.6 MATERIALS AND METHODS 
	
4.6.1 Generation of cDNA from HeLa cell line and clinical samples 
	
CSF samples were collected under the approval of the institutional review boards 
of the University of California San Francisco and San Francisco General Hospital. 
Samples were processed for high-throughput sequencing as previously described.75,76 
Briefly, amplified cDNAs were made from randomly primed total RNA extracted from 
250 μL of CSF or 250 pg of HeLa RNA using the NuGEN Ovation v.2 kit (NuGEN, San 
Carlos, CA, USA) for low nucleic acid content samples. A Nextera protocol (Illumina, 
San Diego, CA, USA) was used to add on a partial sequencing adapter on both sides. 
 
4.6.2 In vitro preparation of the CRISPR/Cas9 complex 
	
	
The Cas9 expression vector, containing an N-terminal MBP tag and C-terminal 
mCherry, was kindly provided by Dr. Jennifer Doudna. The protein was expressed in 
BL21 Rosetta cells for three hours at 18 °C. Cells were pelleted and frozen. Upon 
thawing, cells from a 4 L culture preparation were resuspended in 50 mL of lysis buffer 
(50 mM sodium phosphate pH 6.5, 350 mM NaCl, 1 mM TCEP (tris(2-
carboxyethyl)phosphine), 10 % glycerol) supplemented with 0.5 mM EDTA, 1 μM PMSF 
(phenylmethanesulfonyl), and a single Roche complete EDTA-free protease inhibitor 
tablet (Roche Diagnostics, Indianapolis, IN, USA) and passed through an HC-8000 
homogenizer (Microfluidics, Westwood, MA, USA) five times. The lysate was clarified by 
centrifugation at 20,000 rpm for 45 min at 4 °C and then filtered through a 0.22 μm 
vacuum filtration unit. The filtered lysate was loaded onto three 5 mL HiTrap Heparin HP 
columns (GE Healthcare, Little Chalfont, UK) arranged in series on a GE AKTA Pure 
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system. The columns were washed extensively with lysis buffer, and the protein was 
eluted with a gradient of lysis buffer to buffer B (lysis buffer supplemented with NaCl up 
to 1.5 M). The resulting fractions were analyzed by Coomassie gel, and those 
containing Cas9 (centered around the point on the gradient corresponding to 750 mM 
NaCl) were combined and concentrated down to a volume of 1 mL using 50 K MWCO 
Amicon Ultra-15 Centrifugal Filter Units (EMD Millipore, Billerica, MA, USA) and then 
fed through a 0.22 μm syringe filter. Using the AKTA Pure, the 1 mL of filtered protein 
solution was then injected onto a HiLoad 16/600 Superdex 200 size exclusion column 
(GE Healthcare, Little Chalfont, UK) pre-equilibrated with buffer C (lysis buffer 
supplemented with NaCl up to 750 mM). Resulting fractions were again analyzed by 
Coomassie gel, and those containing purified Cas9 were combined, concentrated, 
supplemented with glycerol up to a final concentration of 50 %, and frozen at −80 °C 
until use. Protein concentration was determined by BCA assay. Yield was approximately 
80 mg from 4 L of bacterial culture. 
sgRNA target sites were selected as described in the main text. DNA templates 
for sgRNAs based on an optimized scaffold were made with a similar method to that 
described Lin et al.139  For each chosen target, a 60mer oligo was purchased including 
the 18-base T7 transcription start site, the targeted 20mer, and the first 22 bases of the 
tracr RNA: (5′-TAATACGACTCACTATAGNN 
NNNNNNNNNNNNNNNNNNGTTTAAGAGCTATG CTGGAAAC-3′). This was mixed 
with a 90mer representing the 3′ end of the sgRNA on the opposite strand (5′- 
AAAAAAAGCACCGACTCGGTGCCACTTTTTC 
AAGTTGATAACGGACTAGCCTTATTTAAACTTGC 
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TATGCTGTTTCCAGCATAGCTCTTA-3′). DNA templates for T7 sgRNA transcription 
were then assembled and amplified with a single PCR reaction using primers 5′- 
TAATACGACTCACTATAG-3′ and 5′- AAAAAA AGCACCGACTCGGTGC-3′. The 
resulting 131 base pair (bp) transcription templates, with the sequence 5′- 
TAATACGACTCACTATAGNNNNNNNNNNNNN 
NNNNNNNGTTTAAGAGCTATGCTGGAAACAGCA 
TAGCAAGTTTAAATAAGGCTAGTCCGTTATCAAC 
TTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTT3′, were pooled (for the 
mitochondrial rRNA library), or transcribed separately (for the KRAS experiments). All 
oligos were purchased from IDT (Integrated DNA Technologies, Coralville, IA, USA). 
Transcription was performed using custom-made T7 RNA polymerase 
(RNAP).140,141 In each 50 μL reaction, 300 ng of DNA template was mixed with T7 
RNAP (final concentration 8 ng/μL), buffer (final concentrations of 40 mM Tris pH 8.0, 
20 mM MgCl2, 5 mM DTT, and 2 mM spermidine), and Ambion brand NTPs 
(ThermoFisher Scientific, Waltham, MA, USA) (final concentration 1 mM each ATP, 
CTP, GTP and UTP), and incubated at 37 °C for 4h. Typical yields were 2–20 μg of 
RNA. sgRNAs were purified with a Zymo RNA Clean & Concentrator-5 kit (Zymo 
Research, Irvine, CA, USA), aliquoted, stored at −80 °C, and used only a single time 
after thawing. 
 
4.6.3 CRISPR/Cas9 treatment 
	
To form the ribonucleoprotein (RNP) complex, Cas9 and the sgRNAs were mixed 
at the desired ratio with Cas9 buffer (final concentrations of 50 mM Tris pH 8.0, 100 mM 
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NaCl, 10 mM MgCl2, and 1 mM TCEP), and incubated at 37 °C for 10 min. This 
complex was then mixed with the desired amount of sample cDNA in a total of 20 μL, 
again in the presence of Cas9 buffer, and incubated for 2 h at 37 °C. 
Since Cas9 has high nonspecific affinity for DNA it was necessary to disable and 
remove the Cas9 before continuing.122 For the rRNA depletion samples, 1 μL (at >600 
mAU/mL) of Proteinase K (Qiagen, Hilden, Germany) was added to each sample which 
was then incubated for an additional 15 min at 37 °C. Samples were then expanded to a 
volume of 100 μL and purified with three phenol:chloroform:isoamyl alcohol extractions 
followed by one chloroform extraction in 2 mL Phaselock Heavy tubes (5prime, Hilden, 
Germany). We added 10 μL of 3 M sodium acetate pH 5.5, 3 μL of linear acrylamide 
and 226 μL of 100% ethanol to the 100 μL aqueous phase of each sample. Samples 
were cooled on ice for 30 min. DNA was then pelleted at 4 °C for 45 min, washed once 
with 70% ethanol, dried at room temperature and resuspended in 10 μL water. 
In the case of the KRAS samples, Cas9 was disabled by heating the sample at 
95 °C for 15 min in a thermocycler and then removed by purifying the sample with a 
Zymo DNA Clean & Concentrator-5 kit (Zymo Research, Irvine, CA, USA). 
 
4.6.4 High-throughput sequencing and analysis of sequencing data 
	
Tagmented samples with and without DASH treatment underwent 10–12 cycles 
of additional amplification (Kapa Amplification Kit, Kapa Biosystems, Wilmington, MA, 
USA) with dual-indexing primers. A BluePippin instrument (Sage Science, Beverly, MA, 
USA) was used to extract DNA between 360 and 540 bp. Sequencing libraries were 
purified using the Zymo DNA Clean & Concentrator-5 kit and amplified again on an 
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Opticon qPCR machine (MJ Research, Waltham, MA, USA) using a Kapa Library 
Amplification Kit until the exponential portion of the quantitative PCR signal was found. 
Sequencing libraries were then pooled and re-quantified with a ddPCR Library 
Quantification Kit (Bio-Rad, Hercules, CA, USA). Sequencing was performed on 
portions of one lane in an Illumina HiSeq 4000 instrument using 135 bp paired-end 
sequencing. 
All reads were quality filtered using PriceSeqFilter (v.1.2)91 such that only read 
pairs with less than five ambiguous base calls (defined as Ns or positions with <95% 
confidence based on Phred score) were retained. Filtered reads were aligned to the 
hg38 build of the human genome using the STAR aligner (v.2.4.2a).95 The number of 
mapped reads per gene and fpkm values were calculated using the exon length and 
sequence information encoded in the Gencode v.23 primary annotations (GTF file). 
Library complexity was determined by calculating the reduction in library size after 
clustering using the cd-hit-dup package.96 Pathogen-specific alignments to 16S and 18S 
sequences were accomplished using Bowtie2.60 Per-nucleotide coverage was 
calculated from alignment (SAM/BAM) files using the SAMtools suite and analyzed with 
custom Python scripts utilizing the Pandas data package.142 Plots were generated with 
Matplotlib.143 
 
4.6.5 ddPCR of KRAS mutant DNA 
	
KRAS wild-type DNA was obtained from a healthy consenting volunteer. The 
sample sat until cell separation occurred, and DNA was extracted from the buffy coat 
with the QIAamp Blood Mini Kit (Qiagen, Hilden, Germany). KRAS G12D genomic DNA 
	
	
100	
from the human leukemia cell line CCRF-CEM was purchased from ATCC (Manassas, 
VA, USA). All DNA was sheared to an average of 800 bp using a Covaris M220 
(Covaris, Woburn, USA) following the manufacturer’s recommended settings. Cas9 
reactions occurred as described above. 
A primer/probe pair was designed with Primer3 (v2.1)144 targeting the relatively 
common KRAS G12D (c.35G>A) mutation. Reactions were thermocycled according to 
manufacturer protocols using a two-step PCR. An ideal 62 °C annealing/extension 
temperature was determined by a gradient experiment to ensure proper separation of 
FAM and HEX signals. The PCR primers and probes used were as follows (purchased 
from IDT): forward 5′- TAGCTG TATCGTCAAGGCAC-3′, reverse 5′-GGCCTGCTGAA 
AATGACTGA-3′; wild-type probe, 5′-/5HEX/TGCCT 
ACGC/ZEN/CACAGCTCCA/3IABkFQ/-3′; mutant probe, 5′-/56-
FAM/TGCCTACGC/ZEN/CACAGCT CCA/3IABkFQ/-3′, with <> denoting the mutant 
base location, 5HEX and 56-FAM denoting the HEX and FAM reporters, and ZEN and 
3IABkFQ denoting the internal and 3′ quenchers. Original samples and those subjected 
to DASH were measured with the ddPCR assay on a Bio-Rad QX100 Droplet Digital 
PCR system (Bio-Rad, Hercules, CA, USA), following the manufacturer’s instructions for 
droplet generation, PCR amplification, and droplet reading, and using best practices. 
Pure CCRF-CEM samples were approximately 30% G12D and 70% wild type; all 
calculations of starting mixtures were made based on this starting ratio. 
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4.6.6 Ethics  
	
CSF samples, as well as a whole blood sample for the KRAS negative control, 
were collected under the approval of the institutional review boards of the University of 
California San Francisco and San Francisco General Hospital (IRB number 13-12236). 
All experimental methods comply with the Helsinki Declaration. 
 
4.6.7 Availability of data and materials 
	
All sequencing data for human subjects has been deposited to NCBI’s database 
of Genotypes and Phenotypes (dbGaP) and can be accessed at 
http://www.ncbi.nlm.nih.gov/gap by entering study accession number phs001067.v1.p1. 
Sequencing data for HeLa samples has been deposited as a separate BioProject in 
NCBI’s Sequence Read Archive (SRA) and can be found at 
http://www.ncbi.nlm.nih.gov/bioproject by entering study accession number 
PRJNA311047. Reagents are available upon request from J.L.D 
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4.7 FIGURES 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 - DASH conceptual figure. 
pyogenes Cas9 protein binds specifically to 
DNA targets that match the ‘NGG’ 
protospacer adjacent motif (PAM) site. 
Additional sequence specificity is conferred 
by a single guide RNA (sgRNA) with a 20-
nucleotide hybridization domain. DNA 
double strand cleavage occurs three 
nucleotides upstream of the PAM site. b 
Depletion of Abundant Sequences by 
Hybridization (DASH) is used to target 
regions that are present at a 
disproportionately high copy number in a 
given next-generation sequencing library 
following tagmentation or flanking 
sequencing adaptor placement. Only non-
targeted regions that have intact adaptors on 
both ends of the same molecule are 
subsequently amplified and represented in 
the final sequencing library. 
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Figure 4.2 - DASH targeting abundant 
mitochondrial rRNA in Hela extrations  A.) 
Normalized coverage plots showing 
alignment to the full-length human 
mitochondrial chromosome. Before 
treatment, three distinct peaks representing 
the 12S and 16S ribosomal subunits 
characteristically account for a large majority 
of the coverage (>60 % of total mapped 
reads). After treatment, the peaks are 
virtually eliminated — with 12S and 16S 
signatures reduced 1000-fold to 0.055% of 
mapped reads. B.) Coverage plot of targeted 
region with 12S and 16S gene boundaries 
across the top.  Red arrowheads represent 
sgRNA target sites. We chose 54 target 
sites, spaced approximately 50 bp apart. C.) 
Scatterplot of the log(fpkm) values per 
human gene in the control versus treated 
samples illustrate the significant reduction in 
reads mapping to the targeted 12S and 16S 
genes. DASH treatment results in 82 and 
105-fold reductions in coverage for the 12S 
and 16S subunits, respectively. DASH 
results in 2.38-fold enrichment in reads 
mapped to untargeted transcripts. R2 value 
(0.979) indicates minimal off-target 
depletion. Between replicates, the R2 
coefficient between fpkm values across all 
genes is 0.994, indicating high reproducibility 
(three replicates). Notably, one gene, MT-
RNR2-L12 (MT-RNR2-like pseudogene), 
shows significant depletion in the DASHed 
samples compared with the control 
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Figure 4.3 - DASH'ed clinical samples. Normalized coverage plots of DASH-treated (orange) 
and untreated (blue) libraries generated from patient cerebrospinal fluid (CSF) samples with 
confirmed infections. Targeted mitochondrial rRNA genes (left) and representative genes for 
pathogen diagnosis (right) are depicted for the following: patient 1, Balamuthia mandrillaris (a), 
patient 2, Cryptococcus neoformans (b), patient 3, Taenia solium (c). Across all cases, the DASH 
technique significantly reduced the coverage of human 12S and 16S genes by an average of 7.5-
fold while increasing the coverage depth for pathogenic sequences by an average 5.9-fold. See 
Table 4.1 for relevant data. 
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Figure 4.4 - DASH in cancer.	A.) DASH is 
used to selectively deplete one allele while 
keeping the other intact. An sgRNA in 
conjunction with Cas9 targets a wild-type 
(WT) KRAS sequence. However, since the 
G12D (c.35G>A) mutation disrupts the PAM 
site, Cas9 does not efficiently cleave the 
mutant KRAS sequence. Subsequent 
amplification of all alleles using flanking 
primers, as in the case of digital PCR, 
Sanger sequencing, or high-throughput 
sequencing, is only effective for non-cleaved 
and mutant sites. B.) Three human genomic 
DNA samples with varying ratios of wild-type 
to mutant (G12D) KRAS were treated either 
with KRAS-targeted DASH, a non-human 
control DASH, or no DASH. Counts of intact 
wild-type and G12D sequences were then 
measured by droplet digital PCR (ddPCR). 
C.) Same data as in (B), presented as 
percentage of mutant sequences detected. 
Inset shows fold enrichment of the 
percentage of mutant sequences with KRAS-
targeted DASH versus no DASH. For both 
(B) and (C), values and error bars are the 
average and standard deviation, 
respectively, of three independent 
experiments. 
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Figure 4.5 - Concentration-dependent depletion. Scatterplot of log of fragments per kilobase 
of transcript per million mapped reads (log-fpkm) values per human gene comparing HeLa cells 
DASHed with twodifferent Cas9/sgRNA concentrations. 
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Figure 4.6 - Mitochondrial rRNA target sites in mtRNR2L12 
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Figure 4.7 - Patient-specific scatterplots. Scatterplots of the log of fragments per kilobase of 
transcript per million mapped reads (log-fpkm) values per human gene in the DASHed vs. 
untreated patient samples. The slopes of the regression lines (red) indicate the fold enrichment 
in reads mapped to untargeted transcripts. R-squared (R2) values of the regression lines indicate 
minimal off-target depletion. 
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4.8 TABLES 
 
Table 4.1 - Summary of depletetion/enrichment results in DASH-treated CSF 
 
 
 
 
Table 4.2 - sgRNA targeted sequences 
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